Robert Zivadinov MD, PhD

Robert Zivadinov
MD, PhD

Professor of Neurology and Professor of Biomedical Informatics

Jacobs School of Medicine & Biomedical Sciences

Specialty/Research Focus

Alzheimer Disease / Memory Disorders; Bioinformatics; Developmental Neurology; General Neurology; Multiple Sclerosis; Neurodegenerative disorders; Neuroimaging; Neuroimaging Analysis; Neurology; Neuroradiology - Radiology; Parkinson's; Vascular and Interventional Radiology

Contact Information

Buffalo Neuroimaging Analysis Center
D-2 Buffalo General Hospital
100 High St
Buffalo, New York 14203
Phone: (716) 859-7040
Fax: (716) 859-7066
rz4@buffalo.edu

View map

View faculty website

Overview Research Publications Activities Latest News

Professional Summary:

I direct the Buffalo Neuroimaging Analysis Center (BNAC) and have established the center as a world leader in performing quantitative MRI analysis in neurodegenerative disorders. I also direct the Translational Imaging Center at UB’s Clinical Translational Research Center (CTRC). I strive to extend the boundaries of current knowledge about neurological diseases and disorders through innovative imaging research techniques and the application of bioinformatics resources. My efforts are directed toward advancing technical, basic and translational research at UB which will, in turn, advance patient care.

I have secured more than $30 million in research grants for collaborative research projects involving UB investigators as well as national and international collaborators. My research interests include structural and functional quantitative MRI analysis for humans and animals, including lesion/tumor identification and segmentation; perfusion and dynamic contrast-enhanced (DCE) mapping and quantification; fluid flow quantification; functional MRI analysis; diffusion tensor reconstruction and tractography; voxel-wise mapping and image-based group statistical analysis; longitudinal change analysis and tissue/pathology/structure volumetry. I study the application of these techniques in healthy individuals and in patients with various disease states such as multiple sclerosis (MS), stroke, Alzheimer’s disease, Parkinson’s disease, epilepsy, systemic lupus erythematosus and traumatic brain injury. I also concentrate on therapeutic interventions, including therapy directed toward assessing neuroprotective efforts in neurodegenerative disorders as well as the venous function, genetic and neuroepidemiology fields of these diseases.

I direct the neurology resident research program. Over a period of two years, I guide third- and fourth-year medical residents through a rigorous assigned scientific research project that is a critical, required part of their training. In addition, I mentor and supervise undergraduate, master’s and doctoral students and MRI fellows. In this role, I help to educate these trainees on clinical MRI use as well as neuroimaging analysis. I also oversee students and fellows conducting research in neurological disorders. One of the most rewarding experiences in my career is helping young physicians and researchers start successful clinical or research careers.

Education and Training:

PhD, University of Rijeka (2002)
University of Trieste (1999)
MD, University of Trieste (1995)
MS, University of Rijeka (1995)
MD, University of Rijeka (1993)

Employment:

Professor of Biomedical Informatics, Department of Biomedical Informatics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York (2018-present)
Director, Translational Imaging Center, Clinical Translational Research Center Jacobs School of Medicine & Biomedical Sciences (2017-present)
Steering Committee Member, Clinical Translational Research Award, Clinical Translational Research Center Jacobs School of Medicine & Biomedical Sciences (2017-present)
Director, MR Imaging, CTRC, CTRC, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2013-present)
Professor of Neurology, Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences (2011-present)
Clinical Professor of Neurology, Neurology, Florida International University College of Medicine (2009-present)
Director of Residency Research and Fellowship Training Program, University at Buffalo (2004-present)
Director of Buffalo Neuroimaging Analysis Center, Jacobs Neurological Institute (2003-present)
Scientific Consultant, National and International pharmaceutical industry and foundations (1999-present)

Awards and Honors:

Treasurer (2021)
2019 Radiology Editor’s Recognition Award for Reviewing with Distinction (2019)
Exceptional Scholar (2018)
Golden Award (2018)
Richard C. Knudsen Publication Award (2017)
Silver Award of International Society for Neurovascular Disease (2016)
Fellow of American Neurological Association (2015)
Fellow of European Academy of Neurology (2015)
American Academy of Neurology Fellow (2010)
MS Community Champion Award (2010)
Biography included in the 21st ed. of Century Award for Achievement (2005)
Who's Who in Science and Engineering (2003)
Young Scientific Investigator Travel Award (2002)
Young Scientific Investigator Travel Award (2002)
First place for best Poster in Neuroimmunology (2001)
Young Scientific Investigator Travel Award (2001)
Second place for best Oral Communication (2000)

Research Expertise:

Neuroimaging

Research Centers:

Buffalo Neuroimaging Analysis Center
Clinical and Translational Research Center (CTRC)
Jacobs Neurological Institute

Grants and Sponsored Research:

April 2016–December 2021
Physiological mechanisms of a biomarker of recovery from concussion.
National Institute of Health.
Role: Co-Investigator
October 2015–October 2020
Delay discounting as a target for self-regulation in prediabetes.
National Institute of Health.
Role: Co-Investigator
June 2017–June 2020
The effects of working memory training on brain function, structure, and cognition in MS
National Multiple Sclerosis Society
Role: Co-Investigator
$622,839
August 2015–March 2019
CTSA hub - Buffalo Clinical and Translational Research Center
NIH/ NCATS
Role: Contributor
July 2016–July 2018
Cholesterol Biomarkers and Oxysterols in Multiple Sclerosis Progression
NINDS
Role: Co-Investigator
June 2013–December 2017
Open-label, single-blinded, observational, prospective, 24-month, longitudinal, controlled study to assess the efficacy of fingolimod (Gilenya) on development of thalamus pathology and cognitive impairment in patients with RRMS
Novartis, Inc.
Role: Principal Investigator
June 2013–December 2017
An open-label, prospective, observational, single-blinded,longitudinal, cross-over study to evaluate the effect of switching from daily injections of 20 mg glatiramer acetate (GA) to 40mg GA three times per week on thalamic path. in subjects with RRMS.
TEVA Pharmaceuticals, Inc.
Role: Principal Investigator
December 2014–December 2016
Effect of teriflunomide (Aubagio) on cortico-basal ganglionic thalamo cortical gray matter connectivity in the Theiler's Murine Encephalomyelitis Virus model of demyelination.
Genzyme, Inc.
Role: Principal Investigator
October 2014–December 2016
Do higher vitamin A levels improve disease severity progression in relapsing, remitting patients on either glatiramer acetate or interferono-beta disease modifying therapies and normal vitamin D levels.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Role: Co-Investigator
June 2014–December 2016
Intra-arterial Vaospasm trial; A multi-center prospective randomized study.
The University of Texas Health Science Center at Houston
Role: Co-Principal Investigator
May 2014–December 2016
MRI services for double-blind, randomized, parallel-group, multicenter study comparing safety and efficacy of monotherapy with INT131 1 mg or 3 mg administered orally or placebo once daily in treatment naive patients with relapsing/remitting MS.
Intekrin
Role: Co-Principal Investigator
April 2014–December 2016
MRI services for Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL study
Claret Medical
Role: Principal Investigator
December 2013–December 2016
Defining the hierarchy of the anatomic, physiologic, and metabolic neuro-degenerative changes in optic neuritis and multiple sclerosis
Neuro-Ophthalmologic Associates, PC.
Role: Co-Principal Investigator
October 2013–December 2016
Hyperbaric Oxygen therapy for Multiple Sclerosis Relapse.
SUNY Stony Brook
Role: Co-Investigator
March 2013–December 2016
Lipoprotein and lipid metabolism in multiple sclerosis disease progression
National Multiple Sclerosis Society
Role: Principal Investigator
September 2014–December 2015
Effect of teriflunomide (Aubagio) on the prevention of gray matter of gray matter atrophy progression in clinically isolated syndrome patients. The post-hoc, blinded MRI analysis of TOPIC study using advanced MRI assessments.
Genzyme, Inc.
Role: Co-Principal Investigator
August 2014–December 2015
NeuroSTREAM - Neurological Software Tool for Reliable Atrophy Measurement
Novartis, Inc.
Role: Co-Principal Investigator
December 2013–December 2015
A prospective, observational, single-blinded, longitudinal optical coherence tomography study of the effect of glatiramer acetate on retinal nerve fiber layer thickness in patients with relapsing-remitting multiple sclerosis over 24 months.
TEVA Pharmaceuticals, Inc.
Role: Principal Investigator
November 2013–December 2015
MRI analysis of the brain damage occurring with the use of a cerebral protection system in patients undergoing trans-femoral aortic valve implantation.
Claret Medical
Role: Co-Principal Investigator
June 2013–December 2015
The effect of teriflunomide (Aubagio) on gray matter pathology in multiple sclerosis; A 12-month prospective, observational, single-blinded, longitudinal study.
Genzyme, Inc.
Role: Principal Investigator
May 2012–December 2015
Open-label, single-blinded, observational, prospective, 1-year follow-up, controlled study to assess the efficacy of fingolimod (Gilenya) on remyelination and demelynation in patients with relapsing forms of multiple sclerosis.
Novartis, Inc.
Role: Principal Investigator
March 2013–December 2014
a 36 months extension of multinational, multicenter, randomized, parallel-group study performed in subjects with RRMS to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times a week or once we
TEVA Pharmaceuticals, Inc.
Role: Co-Principal Investigator
January 2013–December 2014
Pediatric Imaging in multiple sclerosis
The Annette Funicello Research Fund for Neurological Diseases
Role: Principal Investigator
June 2012–December 2014
A prospective, observational, single-blinded, longitudinal MRI study of the effect of glatiramer acetate on iron deposition in patients with relapsing-remitting multiple sclerosis over 24 months.
TEVA Pharmaceuticals, Inc.
Role: Principal Investigator
May 2012–December 2014
A prospective, observational, single-blinded, longitudinal study of Natalizumab effect on brain atrophy and disability in multiple sclerosis patients over 5 years
Biogen Idec, Inc.
Role: Principal Investigator
January 2010–December 2014
Magnetic resonance imaging (MRI testing of active implantable medical devices (AIMDs)
Greatbatch Medical
Role: Principal Investigator
December 2009–December 2014
Natalizumab Temporary Discontinuation Study (NaTDS)
Biogen Idec, Inc.
Role: Principal Investigator
December 2009–December 2014
Combined transcranial and extracranial venous Doppler evaluation (CTEVD study). Description of the design and interim results of an epidemiological study of the prevalence of chronic cerebrospinal venous insufficiency in MS and related diseases
Direct MS Foundation, Jacquemin Foundation, Bronfman Foundation
Role: Principal Investigator
December 2009–December 2014
PREMiSe Trial: Prospective Randomized Endovascular therapy in Multiple Sclerosis
Direct MS Foundation
Role: Co-Principal Investigator
October 2008–December 2014
Longitudinal analysis of regional brain atrophy and personality change in MS
National Multiple Sclerosis Society
Role: Co-Investigator
October 2008–December 2014
BDNF in multiple sclerosis (Renewal).
National Multiple Sclerosis Society
Role: Co-Investigator
February 2009–June 2014
Evolution of gray matter (GM) atrophy over 4 years in observational study of early interferon (IFN)Î²-1a intramuscular (I.M.) (AvonexÂ® ) treatment in high risk subjects after clinically isolated syndrome (SET substudy)
Biogen Idec, Inc.
Role: Principal Investigator
July 2013–December 2013
The efficacy of fingolimod (Gilenya) on the development of thalamus pathology and cognitive impairment in patients with relapsing forms of Multiple Sclerosis.
Novartis, Inc.
Role: Principal Investigator
March 2013–December 2013
Additional post-hoc analyses in a multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Aetate (GA) injection 40
TEVA Pharmaceuticals, Inc.
Role: Principal Investigator
February 2012–December 2013
Assessment of lesion activity analysis in the Avonex - Steroid - Azathioprine (ASA) study.
Biogen Idec, Inc.
Role: Principal Investigator
December 2009–December 2013
A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) injection 40 mg/ml administered three times
Teva Pharmacuticals, Inc.
Role: Principal Investigator
September 2010–September 2013
Gene-Environmental Interactions in Progression of Multiple Sclerosis
Department of Defense Multiple Sclerosis Research Program of the Office of the Congressionally Directed Medical Research Program
Role: Co-Investigator
September 2009–December 2012
A twenty-four week, two arm, pilot trial to evaluate remyelination/demyelination, gray matter volume and iron deposition in the central nervous system (CNS) and immune status of subjects with relapsing-remitting multiple sclerosis (RRMS) treated with Reb
EMD Serono Inc.
Role: Principal Investigator
January 2011–December 2011
Neurology Lecture Series
Teva Neuroscience, Inc.
Role: Principal Investigator
January 2011–December 2011
Interactive web-based continuing medical education (CME) program: Managing Parkinson's Disease: Diagnosis and Treatment Problems and Solutions
Biogen Idec, Inc.
Role: Principal Investigator
October 2010–December 2011
Interactive web-based continuing medical education (CME) program: Understanding Multiple Sclerosis: Advances in Epidemiology, Pathology, Imaging and Treatment Strategies
Teva Neuroscience, Inc.
Role: Principal Investigator
June 2008–December 2010
Quantitative progressive exercise rehabilitation for post-concussion syndrome.
State University of New York at Buffalo
Role: Co-Investigator
January 2008–December 2010
Clinical and translational research in brain and behavior across the Lifespan.
State University of New York at Buffalo
Role: Co-Investigator
January 2006–December 2010
Application for a pediatric multiple sclerosis center.
National Multiple Sclerosis Society
Role: Co-Investigator
December 2005–December 2010
Neurological indices of CNS Involvement in Non-CNS SLE.
National Institute of Health (NINDS)
Role: Co-Investigator
January 2008–June 2010
Assessment of a potential beneficial role of active CMV infection in MS models
National Multiple Sclerosis Society
Role: Consultant
June 2007–June 2010
Perception and action in sequential behavior.
National Science Foundation
Role: Contributor
January 2007–December 2009
Metabolic cerebral imaging in incipient dementia: Early and long-term value of imaging brain metabolism; A prospective, multi-center randomized study of the impace of regional cerebral metabolic assessment in patients undergoing evaluation for mold cogn
National Institute of Health
Role: Consultant
June 2004–June 2009
Neurocognitive rehabilitation in alcohol treatment
National Institute on Alcohol Abuse and Alcoholism
Role: Contributor
January 2007–December 2008
Multiple Sclerosis surveillance project.
Agency for Toxic Substances and Disease Registry (ATSDR)
Role: Principal Investigator
January 2007–December 2008
Associations between post-traumatic stress symptoms and brain functioning in police officers.
National Institute for Occupational Safety and Health
Role: Contributor
June 2005–December 2008
BDNF in Multiple Sclerosis
National Multiple Sclerosis Society
Role: Co-Investigator
January 2003–December 2008
Advanced Approaches for the Integration and Analysis of Genomic Data.
National Science Foundation
Role: Co-Investigator
January 2007–December 2007
Development of fully-automated software imaging program to provide quantified neuroimaging for stroke
Jog for the Jake Foundation
Role: Principal Investigator
June 2005–December 2007
Predicting neuropsychological defects in MS with regional MTR using a semi-automated extraction technique
National Multiple Sclerosis Society
Role: Co-Principal Investigator
April 2002–March 2007
A longitudinal study of mild cognitive impairment in multiple sclerosis
SUNY Stony Brook
Role: Consultant
January 2004–December 2004
Estimation of State Transition Hazard Functions for a Standard Markov Model of Multiple Sclerosis.
Duke University
Role: Principal Investigator
August 1986–June 1989
Macrophage imaging in patients with active secondary progressive Multiple Sclerosis
National Multiple Sclerosis Society
Role: Co-Investigator

See all (48 more)

Patents:

Intekrin Therapeutics, Inc.: (2019)

Journal Articles:

Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B, Hojnacki DW. (2016) Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years. Eur J Neurol (Jun), 23(6): 1101-1109.
Zivadinov R, Raj B, Ramanathan M, Teter B, Durfee J, Dwyer MG, Bergsland N, Kolb C, Hojnacki D, Benedict RH, Weinstock-Guttman B, Hojnacki DW. (2016) Autoimmune Comorbidities Are Associated with Brain Injury in Multiple Sclerosis. AJNR Am J Neuroradiol (Feb).
Fuchs TA,M,P Dwyer MG, Jakimovski D,P Bergsland N, Ramasamy DR, Weinstock-Guttman B, Benedict RHB, Zivadinov R. (2021) Quantifying disease pathology and predicting disease progression in multiple sclerosis from clinical routine T2-FLAIR MRI. Neuroimage Clin (Oct) doi:10.1016/j.nicl.2021.102705
Bergsland N, Dwyer MG, Jakimovski D,P Weinstock-Guttman B, Zivadinov R. (2021) Diffusion tensor imaging reveals greater microstructure damage in lesional tissue that shrinks into cerebrospinal fluid in multiple sclerosis. J Neuroimaging (Sep) doi:10.1111/jon.12891
Barnett M, Bergsland N, Weinstock-Guttman B, Butzkueven H, Kalincik H, Desmond P, Gaillard F, van Pesch V, Ozakbas S, Rojas JI, Boz C, Altintas A, Wang C, Dwyer MG, Yang S, Jakimovski D,P Kyle K, Ramasamy DP, Zivadinov R. (2021) Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. Neuroimage Clin (Aug) doi:10.1016/j.nicl.2021.102802
Jakimovski D,P Zivadinov R, Vaughn C, Ozel O, Weinstock-Guttman B. (2021) Clinical effects associated with five-year retinal nerve fiber layer thinning in multiple sclerosis. J Neurol Sci (Aug) doi:10.1016/j.jns.2021.117552
Jakimovski D,P Benedict RHB, Weinstock-Guttman B, Ozel O, Fuchs TA M,P Lincoff N, Bergsland N, Dwyer MG, Zivadinov R. (2021) Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate or both?. J Neurol (Jul) doi:10.1007/s00415-021-10437-5
Lansky AJ, Makkar R, Nazif T, Pietras C, Forrest J, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Parise H, Gambone L, Kodali S, Baumbach A, Moses J on behalf of the REFLECT I Trial Investigators. (2021) A Randomized Evaluation oF the TriGuard™ HDH cerebral embolic protection device to reduce the impact of cerebral embolic LEsions after transCatheter aortic valve implanTation - The REFLECT I trial. Eur Heart (Jul) doi:10.1093/eurheartj/ehab213
Jaworski MG, Fuchs TA, Dwyer MG, Wojcik C, Zivadinov R, Weinstock-Guttman B, Benedict RH, Dwyer, III MG. (2021) Conscientiousness and deterioration in employment status in multiple sclerosis over 3â€‰years. Mult Scler (Jun)1352458520-1352458520. doi:10.1177/1352458520946019
Morrow SA, Conway D, Fuchs T, Wojcik C, Unverdi M, Yasin F, Pol J, Eckert S, Hojnacki DH, Dwyer M, Zivadinov R, Weinstock-Guttman B, Benedict RH, Hojnacki DW. (2021) Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapses. Mult Scler (Jun)1352458520-1352458520. doi:10.1177/1352458520973618
Hildesheim FE,F Benedict RHB, Zivadinov R, Dwyer MG, Fuchs T, M,P Jakimovski D, P Weinstock-Guttman B, Bergsland N. (2021) Nucleus basalis of Meynert damage and cognition in patients with multiple sclerosis. J Neurol (May) doi:10.1007/s00415-021-10594-7
Wojcik C, Fuchs TA M,P Tran H, Dwyer MG, Jakimovski D,P Weinstock-Guttman B, Zivadinov R, Eshaghi A, Benedict RHB. (2021) Staging and stratifying cognitive dysfunction in multiple sclerosis. Mult Scler (May) doi:10.1177/13524585211011390
McComb M, Browne RW, Bodziak ML, Jakimovski D,P Bergsland N, Maceski A, Weinstock-Guttman B, Kuhle J, Zivadinov R, Ramanathan M. (2021) The cholesterol autoxidation products, 7-ketocholesterol and 7ß-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. (May) doi:10.1016/j.msard.2021.102864
Schweser F, Hagemeier J, Dwyer MG, Bergsland N, Hametner S, Weinstock-Guttman B, Zivadinov R. (2021) Decreasing brain iron in multiple sclerosis: The difference between concentration and content in iron MRI. Hum Brain Mapp (Apr) doi:10.1002/hbm.25306
Nazif T, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, Horwitz P, Makkar R, Stoler R, Forrest J, Messe S, Dickerman S, Brennan J, Zivadinov R, Dwyer MG, and Lansky AJ on behalf of the REFLECT II Trial Investigators. (2021) Randomized Evaluation of the TriGuard 3 cerebral embolic protection after transcatheter aortic valve replacement: REFLECT II. JACC Cardiovasc Interv (Mar) doi:10.1016/j.jcin.2020.11.011
14. Uher T, Krasensky J, Malpas CB, Bergsland N, Dwyer MG, Vaclav Capek, Havrdova EK, Vaneckova M, Horakova D, Zivadinov R, Kalincik T. (2021) Evolution of brain volume loss rates in early stages of multiple sclerosis. (Mar) doi:10.1212/NXI.0000000000000979
Dwyer MG, Lyman C, Ferrari H, Bergsland N, Fuchs T,M,P Jakimovski D,P Weinstock-Guttmann B, Benedict RHB, Riolo J, Silva D, Zivadinov R. (2021) Artificial intelligence based thalamic volumetry is fast, reliable, and generalizable to large, heterogeneous datasets using only clinical quality T2-FLAIR MRI. (Mar) doi:10.1016/j.nicl.2021.102652
Uher T, Bergsland N, Krasensky J, Dwyer MG, Andelova M, Sobisek L, Havrdova EK, Horakova D, Zivadinov R, Vaneckova M, Dwyer, III MG. (2021) Interpretation of Brain Volume Increase in Multiple Sclerosis. J Neuroimaging (Mar) doi:10.1111/jon.12816
Bergsland N, Benedict RHB, Dwyer MG, Fuchs TA, Jakimovski D, Schweser F, Tavazzi E, Weinstock-Guttman B, Zivadinov R. (2021) Thalamic Nuclei Volumes and Their Relationships to Neuroperformance in Multiple Sclerosis: A Cross-Sectional Structural MRI Study. J Magn Reson Imaging (Mar), 53(3): 731-739. doi:10.1002/jmri.27389
Jakimovski D, Benedict RHB, Weinstock-Guttman B, Ozel O, Fuchs TA, Lincoff N, Bergsland N, Dwyer MG, Zivadinov R, Dwyer, III MG. (2021) Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?. J Neurol (Feb).
Uher T, McComb M, Galkin S, Srpova B, Oechtering J, Barro C, Tyblova M, Bergsland N, Krasensky J, Dwyer MG, Havrdova E, Posova H, Vaneckova M, Zivadinov R, Horakova D, Kuhle J, Ramanathan M. (2021) Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult Scler (Feb) doi:10.1177/1352458520912379
Jacobsen C, Benedict RHB, Zivadinov R, Myhr KM, Dalaker TO, Dalen I, Bergsland N, Farbu E. (2021) Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: a 10-year follow-up study. Mult Scler J Exp Transl Clin. (Feb) doi:10.1177/2055217321992394
Laganà MM, Jakimovski D,P Bergsland N, Dwyer MG, Baglio F, Zivadinov R. (2021) Measuring aqueduct of sylvius cerebrospinal fluid flow in multiple sclerosis using different software. (Feb) doi:10.3390/diagnostics11020325
Ashton K, Fuchs TA, Oship D, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Vaughn C, Weinstock-Guttman B, Benedict RHB, Dwyer MG, Dwyer, III MG. (2021) Diagnosis of depression in multiple sclerosis is predicted by frontal-parietal white matter tract disruption. J Neurol (Jan), 268(1): 169-177. doi:10.1007/s00415-020-10110-3
Jakimovski D, Zivadinov R, Bergsland N, Ramasamy DP, Hagemeier J, Genovese AV, Hojnacki D, Weinstock-Guttman B, Dwyer MG, Hojnacki DW. (2021) Clinical feasibility of longitudinal lateral ventricular volume measurements on T2-FLAIR across MRI scanner changes. Neuroimage Clin (Jan), 29: 102554-102554.
Hildesheim FE, Ramasamy DP, Bergsland N, Jakimovski D, Dwyer MG, Hojnacki D, Lizarraga AA, Kolb C, Eckert S, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2021) Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. Mult Scler Relat Disord (Jan), 47: 102653-102653.
Pol S, Liang S, Schweser F, Dhanraj R, Schubart A, Preda M, Sveinsson M, Ramasamy DP, Dwyer MG, Weckbecker G, Zivadinov R. (2021) Subcutaneous anti-CD20 antibody treatment delays gray matter atrophy in human myelin oligodendrocyte glycoprotein-induced EAE mice. Exp Neurol (Jan), 335: 113488-113488. doi:10.1016/j.expneurol.2020.113488
Hildesheim FE,F Ramasamy DP, Bergsland N, Jakimovski D ,P Dwyer MG, Hojnacki D, Lizarraga AA, Kolb C, Eckert S, Weinstock-Guttman B, Zivadinov R. (2021) Leptomeningeal, dura mater and meningeal vessel wall enhancements in multiple sclerosis. . Mult Scler (Jan) doi:10.1016/j.msard.2020.102653
Benedict RH, Pol J, Yasin F, Hojnacki D, Kolb C, Eckert S, Tacca B, Drake A, Wojcik C, Morrow SA, Jakimovski D, Fuchs TA, Dwyer MG, Zivadinov R, Weinstock-Guttman B, Hojnacki DW. (2021) Recovery of cognitive function after relapse in multiple sclerosis. Mult Scler (Jan), 27(1): 71-78. doi:10.1177/1352458519898108
Zivadinov R, Dwyer MG, Carl E, Poole EM, Cavalier S, Briassouli P, Bergsland N, Dwyer, III MG. (2020) Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. Ther Adv Neurol Disord (Nov), 13: 1756286420-1756286420.
Jakimovski D, Dujmic D, Hagemeier J, Ramasamy DP, Bergsland N, Dwyer MG, Eckert S, Kolb C, Lizarraga A, Hojnacki D, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2020) Late onset multiple sclerosis is associated with more severe ventricle expansion. Mult Scler Relat Disord (Nov), 46: 102588-102588.
Subramanian K, Utriainen D, Ramasamy DP, Sethi SK, Schweser F, Beaver J, Hagemeier J, Weinstock-Guttman B, Rajagovindan R, Zivadinov R, Haacke EM. (2020) Longitudinal Magnetic Resonance Imaging of Cerebral Microbleeds in Multiple Sclerosis Patients. Diagnostics (Basel) (Nov), 10(11).
Jakimovski D, Zivadinov R, Dwyer MG, Bergsland N, Ramasamy DP, Browne RW, Weinstock-Guttman B, Ramanathan M, Dwyer, III MG. (2020) High density lipoprotein cholesterol and apolipoprotein A-I are associated with greater cerebral perfusion in multiple sclerosis. J Neurol Sci (Nov), 418: 117120-117120.
Zivadinov R, Schweser F, Dwyer MG, Pol S. (2020) Detection of Monocyte/Macrophage and Microglia Activation in the TMEV Model of Chronic Demyelination Using USPIO-Enhanced Ultrahigh-Field Imaging. J Neuroimaging (Nov), 30(6): 769-778.
Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG, Dwyer, III MG. (2020) Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis. Mult Scler (Oct), 26(11): 1433-1436.
Jakimovski D, Bergsland N, Dwyer MG, Ramasamy DP, Ramanathan M, Weinstock-Guttman B, Zivadinov R, Dwyer, III MG. (2020) Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis. Diagnostics (Basel) (Sep), 10(9).
Jakimovski D, Bergsland N, Dwyer MG, Traversone J, Hagemeier J, Fuchs TA, Ramasamy DP, Weinstock-Guttman B, Benedict RHB, Zivadinov R, Dwyer, III MG. (2020) Cortical and Deep Gray Matter Perfusion Associations With Physical and Cognitive Performance in Multiple Sclerosis Patients. Front Neurol (Jul), 11: 700-700.
McComb M, Parambi R, Browne RW, Bodziak ML, Jakimovski D, Bergsland N, Maceski A, Weinstock-Guttman B, Kuhle J, Zivadinov R, Ramanathan M. (2020) Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Mult Scler Relat Disord (Jul), 45: 102389-102389.
Tavazzi E, Bergsland N, Kuhle J, Jakimovski D, Ramanathan M, Maceski AM, Tomic D, Hagemeier J, Kropshofer H, Leppert D, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R, Dwyer, III MG. (2020) A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. J Neurol (Mar), 267(3): 802-811.
Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Ramasamy DP, Hojnacki D, Lizarraga AA, Kolb C, Eckert S, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2020) Disability Improvement Is Associated with Less Brain Atrophy Development in Multiple Sclerosis. AJNR Am J Neuroradiol (Jan), 41(9): 1577-1583.
Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2020) Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up. Eur J Neurol (Jan), 27(1): 188-188.
Jakimovski D, Ramanathan M, Weinstock-Guttman B, Bergsland N, Ramasamay DP, Carl E, Dwyer MG, Zivadinov R, Dwyer, III MG. (2020) Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. Mult Scler (Jan), 26(3): 322-332.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R, Dwyer, III MG. (2020) Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines (Basel) (Jan), 8(1).
Fuchs TA, Ziccardi S, Benedict RHB, Bartnik A, Kuceyeski A, Charvet LE, Oship D, Weinstock-Guttman B, Wojcik C, Hojnacki D, Kolb C, Escobar J, Campbell R, Tran HD, Bergsland N, Jakimovski D, Zivadinov R, Dwyer MG, Hojnacki DW. (2020) Functional Connectivity and Structural Disruption in the Default-Mode Network Predicts Cognitive Rehabilitation Outcomes in Multiple Sclerosis. J Neuroimaging (Jan), 30(4): 523-530.
Jakimovski D, Bergsland N, Dwyer MG, Hagemeier J, Ramasamy DP, Szigeti K, Guttuso T, Lichter D, Hojnacki D, Weinstock-Guttman B, Benedict RHB, Zivadinov R, Hojnacki DW. (2020) Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson's disease, mild cognitive impairment, Alzheimer's disease, and elderly healthy controls. Neurobiol Aging (Jan), 90: 84-92.
Jakimovski D, Zivadinov R, Weinstock-Guttman B, Bergsland N, Dwyer MG, Lagana MM, Dwyer, III MG. (2020) Longitudinal analysis of cerebral aqueduct flow measures: multiple sclerosis flow changes driven by brain atrophy. Fluids Barriers CNS (Jan), 17(1): 9-9.
Tavazzi E, Zivadinov R, Dwyer MG, Jakimovski D, Singhal T, Weinstock-Guttman B, Bergsland N, Dwyer, III MG. (2020) MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Rev Neurother (Jan), 20(8): 821-834.
Jakimovski D, Zivadinov R, Bergsland N, Ramasamy DP, Hagemeier J, Weinstock-Guttman B, Kolb C, Hojnacki D, Dwyer MG, Hojnacki DW. (2020) Sex-Specific Differences in Life Span Brain Volumes in Multiple Sclerosis. J Neuroimaging (Jan), 30(3): 342-350.
Tavazzi E, Jakimovski D, Kuhle J, Hagemeier J, Ozel O, Ramanathan M, Barro C, Bergsland N, Tomic D, Kropshofer H, Leppert D, Michalak Z, Lincoff N, Dwyer MG, Benedict RHB, Weinstock-Guttman B, Zivadinov R, Dwyer, III MG. (2020) Serum neurofilament light chain and optical coherence tomography measures in MS: A longitudinal study. Neurol Neuroimmunol Neuroinflamm (Jan), 7(4).
Karthikeyan B, Sonkawade SD, Pokharel S, Preda M, Schweser F, Zivadinov R, Kim M, Sharma UC, Sharma U. (2020) Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction. Magn Reson Imaging (Jan), 66: 208-218.
Fuchs TA, Wojcik C, Wilding GE, Pol J, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Benedict RH, Dwyer, III MG. (2020) Trait Conscientiousness predicts rate of longitudinal SDMT decline in multiple sclerosis. Mult Scler (Jan), 26(2): 245-252.
Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG, Dwyer, III MG. (2019) Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis. Hum Brain Mapp (Dec), 40(18): 5231-5241.
Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R. (2019) Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders. CNS Drugs (Nov), 33(11): 1073-1086.
Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2019) Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis. Radiology (Nov), 293(2): 424-433.
Karthikeyan B, Sonkawade SD, Pokharel S, Preda M, Schweser F, Zivadinov R, Kim M, Sharma UC, Sharma U. (2019) Tagged cine magnetic resonance imaging to quantify regional mechanical changes after acute myocardial infarction. Magn Reson Imaging (Oct).
Jakimovski D, Zivadinov R, Pelizzari L, Browne RW, Weinstock-Guttman B, Ramanathan M. (2019) Lipoprotein(a) Levels Are Associated with the Size of Extracranial Arteries in Multiple Sclerosis. J Vasc Res (Sep), 57(1): 16-23.
Fuchs TA, Ziccardi S, Dwyer MG, Charvet LE, Bartnik A, Campbell R, Escobar J, Hojnacki D, Kolb C, Oship D, Pol J, Shaw MT, Wojcik C, Yasin F, Weinstock-Guttman B, Zivadinov R, Benedict RHB, Hojnacki DW. (2019) Response heterogeneity to home-based restorative cognitive rehabilitation in multiple sclerosis: An exploratory study. Mult Scler Relat Disord (Sep), 34: 103-111.
Zivadinov R, Dwyer MG, Dwyer, III MG. (2019) Network Dynamics and Cognitive Impairment in Multiple Sclerosis: Functional MRI-based Decoupling of Complex Relationships. Radiology (Aug), 292(2): 458-459.
Browne RW, Jakimovski D, Ziliotto N, Kuhle J, Bernardi F, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2019) High-density lipoprotein cholesterol is associated with multiple sclerosis fatigue: AÂ fatigue-metabolism nexus?. J Clin Lipidol (Jul), 13(4): 654-663.
Gandhi S, Marr K, Mancini M, Caprio MG, Jakimovski D, Chandra A, Hagemeier J, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2019) No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5â€‰years. BMC Neurol (Jun), 19(1): 121-121.
Deshpande HU, Mellis AM, Lisinski JM, Stein JS, Koffarnus MN, Paluch R, Schweser F, Zivadinov R, LaConte SM, Epstein LH, Bickel WK. (2019) Reinforcer pathology: Common neural substrates for delay discounting and snack purchasing in prediabetics. Brain Cogn (Jun), 132: 80-88.
Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T. (2019) Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease. Mov Disord (Jun).
Fellows Maxwell K, Bhattacharya S, Bodziak ML, Jakimovski D, Hagemeier J, Browne RW, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2019) Oxysterols and Apolipoproteins in Multiple Sclerosis: A 5-year Follow-up Study. J Lipid Res (May).
Bergsland N, Ramasamy D, Tavazzi E, Hojnacki D, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2019) Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study. AJNR Am J Neuroradiol (Apr), 40(4): 620-625.
Pol S, Schweser F, Bertolino N, Preda M, Sveinsson M, Sudyn M, Babek N, Zivadinov R. (2019) Characterization of leptomeningeal inflammation in rodent experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. Exp Neurol (Apr), 314: 82-90.
Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B, Hojnacki DW. (2019) Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. J Clin Med (Mar), 8(3).
Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R. (2019) Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study. J Neurol (Feb).
Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F. (2019) Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls. Neuroimage (Feb), 186: 308-320.
Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG, Dwyer, III MG. (2019) A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS. AJNR Am J Neuroradiol (Jan), 40(3): 446-452.
Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2019) Aging and Brain Atrophy in Multiple Sclerosis. J Neuroimaging (Jan), 29(4): 527-535.
Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D, Hojnacki DW. (2019) Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS. Neurology (Jan), 93(6): 611-623.
Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S, Dwyer, III MG. (2019) Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study. J Comp Eff Res (Jan), 8(5): 305-316.
Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2019) Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol (Jan), 26(1): 87-88.
Fellows Maxwell K, Bhattacharya S, Bodziak ML, Jakimovski D, Hagemeier J, Browne RW, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2019) Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study. J Lipid Res (Jan), 60(7): 1190-1198.
Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R, Dwyer, III MG. (2019) Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis. J Neuroimaging (Jan), 29(5): 615-623.
Pol S, Sveinsson M, Sudyn M, Babek N, Siebert D, Bertolino N, Modica CM, Preda M, Schweser F, Zivadinov R. (2019) Teriflunomide's Effect on Glia in Experimental Demyelinating Disease: A Neuroimaging and Histologic Study. J Neuroimaging (Jan), 29(1): 52-61.
Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R, Dwyer, III MG. (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol (Jan), 6(9): 1757-1770.
Schweser F, Zivadinov R. (2018) Quantitative susceptibility mapping (QSM) with an extended physical model for MRI frequency contrast in the brain: a proof-of-concept of quantitative susceptibility and residual (QUASAR) mapping. NMR Biomed (Dec), 31(12): 3999-3999.
Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2018) Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. AJNR Am J Neuroradiol (Dec), 39(12): 2237-2242.
Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F, Hojnacki DW. (2018) Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. Radiology (Nov), 289(2): 487-496.
Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Benedict RHB, Zivadinov R. (2018) Thalamic white matter in multiple sclerosis: A combined diffusion-tensor imaging and quantitative susceptibility mapping study. Hum Brain Mapp (Oct), 39(10): 4007-4017.
Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R, Dwyer, III MG. (2018) Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage. J Neurol Sci (Oct), 393: 128-134.
Baker JG, Leddy JJ, Hinds AL, Haider MN, Shucard J, Sharma T, Hernandez S, Durinka J, Zivadinov R, Willer BS. (2018) An Exploratory Study of Mild Cognitive Impairment of Retired Professional Contact Sport Athletes. J Head Trauma Rehabil (Sep), 33(5): 16-23.
Willer BS, Zivadinov R, Haider MN, Miecznikowski JC, Leddy JJ. (2018) A Preliminary Study of Early-Onset Dementia of Former Professional Football and Hockey Players. J Head Trauma Rehabil (Sep), 33(5): 1-8.
Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS. (2018) Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage. J Head Trauma Rehabil (Sep), 33(5): 24-32.
Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Hojnacki DW. (2018) The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. CNS Drugs (Aug), 32(8): 763-770.
Guttuso T, Bergsland N, Hagemeier J, Lichter DG, Pasternak O, Zivadinov R, Guttuso, Jr. TJ. (2018) Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease. AJNR Am J Neuroradiol (Mar), 39(3): 479-484.
Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R, Dwyer, III MG. (2018) Establishing pathological cut-offs for lateral ventricular volume expansion rates. Neuroimage Clin (Feb), 18: 494-501.
Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D, Hojnacki DW. (2018) Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis. AJNR Am J Neuroradiol (Feb).
Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D, Dwyer, III MG. (2018) Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS. AJNR Am J Neuroradiol (Feb), 39(2): 289-295.
Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B, Dwyer, III MG. (2018) Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS. J Neuroimaging (Jan), 28(4): 399-405.
Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M, Zivadinov R. (2018) Hemostasis biomarkers in multiple sclerosis. Eur J Neurol (Jan), 25(9): 1169-1176.
Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D, Weinstock-Guttman B, Hojnacki DW. (2018) Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. J Neurol Sci (Jan), 388: 175-181.
Fuchs TA, Carolus K, Benedict RHB, Bergsland N, Ramasamy D, Jakimovski D, Weinstock-Guttman B, Kuceyeski A, Zivadinov R, Dwyer MG, Dwyer, III MG. (2018) Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study. AJNR Am J Neuroradiol (Jan), 39(8): 1480-1486.
Schweser F, Raffaini Duarte Martins AL, Hagemeier J, Lin F, Hanspach J, Weinstock-Guttman B, Hametner S, Bergsland N, Dwyer MG, Zivadinov R. (2018) Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality. Neuroimage (Jan), 167: 438-452.
Lazar RM, Pavol MA, Bormann T, Dwyer MG, Kraemer C, White R, Zivadinov R, Wertheimer JC, ThÃ¶ne-Otto A, Ravdin LD, Naugle R, Mechanic-Hamilton D, Garmoe WS, Stringer AY, Bender HA, Kapadia SR, Kodali S, Ghanem A, Linke A, Mehran R, Virmani R, Nazif T, Parhizgar A, Leon MB, Dwyer, III MG. (2018) Neurocognition and Cerebral Lesion Burden in High-Risk Patients Before Undergoing Transcatheter Aortic Valve Replacement: Insights From the SENTINEL Trial. JACC Cardiovasc Interv (Jan), 11(4): 384-392.
Roy S, Drake A, Fuchs T, Dwyer MG, Zivadinov R, Chapman BP, Weinstock-Guttman B, Benedict RH, Dwyer, III MG. (2018) Longitudinal personality change associated with cognitive decline in multiple sclerosis. Mult Scler (Jan)1352458517-1352458517.
Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R, Dwyer, III MG. (2018) Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis. J Neuroimaging (Jan), 28(5): 490-495.
Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B, Hojnacki DW. (2018) Effect of switching from glatiramer acetate 20â€¯mg/daily to glatiramer acetate 40â€¯mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. J Neurol Sci (Jan), 387: 152-156.
Schweser F, Preda M, Zivadinov R. (2018) Susceptibility Weighted MRI in Rodents at 9.4 T. Methods Mol Biol (Jan), 1718: 205-234.
Uher T, Krasensky J, Sobisek L, Seidl Z, Bergsland N, Dwyer MG, Kubala Havrdova E, Zivadinov R, Horakova D, Vaneckova M, Dwyer, III MG. (2018) The Role of High-Frequency MRI Monitoring in the Detection of Brain Atrophy in Multiple Sclerosis. J Neuroimaging (Jan), 28(3): 328-337.
Fuchs TA, Dwyer MG, Kuceyeski A, Choudhery S, Carolus K, Li X, Mallory M, Weinstock-Guttman B, Jakimovski D, Ramasamy D, Zivadinov R, Benedict RHB, Dwyer, III MG. (2018) White matter tract network disruption explains reduced conscientiousness in multiple sclerosis. Hum Brain Mapp (Jan), 39(9): 3682-3690.
Hagemeier J, Ramanathan M, Schweser F, Dwyer MG, Lin F, Bergsland N, Weinstock-Guttman B, Zivadinov R. (2017) Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. Neuroimage Clin (Nov), 17: 530-540.
Bergsland N, Horakova D, Dwyer MG, Uher T, Vaneckova M, Tyblova M, Seidl Z, Krasensky J, Havrdova E, Zivadinov R, Dwyer, III MG. (2017) Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. Neuroimage Clin (Nov), 17: 444-451.
Hanspach J, Dwyer MG, Bergsland NP, Feng X, Hagemeier J, Bertolino N, Polak P, Reichenbach JR, Zivadinov R, Schweser F. (2017) Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA). J Magn Reson Imaging (Nov), 46(5): 1474-1484.
Uher T, Krasensky J, Vaneckova M, Sobisek L, Seidl Z, Havrdova E, Bergsland N, Dwyer MG, Horakova D, Zivadinov R, Dwyer, III MG. (2017) A Novel Semiautomated Pipeline to Measure Brain Atrophy and Lesion Burden in Multiple Sclerosis: A Long-Term Comparative Study. J Neuroimaging (Nov), 27(6): 620-629.
Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B, Hojnacki DW. (2017) Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler (Sep), 23(10): 1336-1345.
Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R, Hojnacki DW. (2017) Ocrelizumab: a B-cell depleting therapy for multiple sclerosis. Expert Opin Biol Ther (Sep), 17(9): 1163-1172.
Modica CM, Schweser F, Sudyn ML, Bertolino N, Preda M, Polak P, Siebert DM, Krawiecki JC, Sveinsson M, Hagemeier J, Dwyer MG, Pol S, Zivadinov R. (2017) Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis. PLoS One (Aug), 12(8): 0182729-0182729.
Woodward MR, Dwyer MG, Bergsland N, Hagemeier J, Zivadinov R, Benedict RH, Szigeti K, Dwyer, III MG. (2017) Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease. Psychiatry Res Neuroimaging (Aug), 266: 90-95.
Dwyer MG, Silva D, Bergsland N, Horakova D, Ramasamy D, Durfee J, Vaneckova M, Havrdova E, Zivadinov R, Dwyer, III MG. (2017) Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosis. Neuroimage Clin (Jun), 15: 769-779.
Mukhopadhyay S, Fellows K, Browne RW, Khare P, Krishnan Radhakrishnan S, Hagemeier J, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2017) Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Mult Scler (May), 23(6): 792-801.
Hagemeier J, Zivadinov R, Dwyer MG, Polak P, Bergsland N, Weinstock-Guttman B, Zalis J, Deistung A, Reichenbach JR, Schweser F. (2017) Changes of deep gray matter magnetic susceptibility over 2Â years in multiple sclerosis and healthy control brain. Neuroimage Clin (Apr), 18: 1007-1016.
Belov P, Magnano C, Krawiecki J, Hagemeier J, Bergsland N, Beggs C, Zivadinov R. (2017) Age-related brain atrophy may be mitigated by internal jugular vein enlargement in male individuals without neurologic disease. Phlebology (Mar), 32(2): 125-134.
Feng X, Deistung A, Dwyer MG, Hagemeier J, Polak P, Lebenberg J, Frouin F, Zivadinov R, Reichenbach JR, Schweser F. (2017) An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM). Magn Reson Imaging (Feb), 39: 110-122.
Uher T, Havrdova E, Sobisek L, Krasensky J, Vaneckova M, Seidl Z, Tyblova M, Ramasamy D, Zivadinov R, Horakova D. (2017) Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?. Mult Scler (Feb), 23(2): 242-252.
Lansky AJ, MessÃ© SR, Brickman AM, Dwyer M, Bart van der Worp H, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Scala Moy C, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. (2017) Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials. Eur Heart J (Feb).
Lansky AJ, MessÃ© SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. (2017) Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol (Feb), 69(6): 679-691.
Uher T, Fellows K, Horakova D, Zivadinov R, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Bergsland N, Weinstock-Guttman B, Havrdova E, Ramanathan M. (2017) Serum lipid profile changes predict neurodegeneration in interferon-Î²1a-treated multiple sclerosis patients. J Lipid Res (Feb), 58(2): 403-411.
Mokin M, Zivadinov R, Dwyer MG, Lazar RM, Hopkins LN, Siddiqui AH, Dwyer, III MG. (2017) Transcatheter aortic valve replacement: perioperative stroke and beyond. Expert Rev Neurother (Jan), 17(4): 327-334.
Kapadia SR, Kodali S, Makkar R, Mehran R, Lazar RM, Zivadinov R, Dwyer MG, Jilaihawi H, Virmani R, Anwaruddin S, Thourani VH, Nazif T, Mangner N, Woitek F, Krishnaswamy A, Mick S, Chakravarty T, Nakamura M, McCabe JM, Satler L, Zajarias A, Szeto WY, Svensson L, Alu MC, White RM, Kraemer C, Parhizgar A, Leon MB, Linke A. (2017) Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. J Am Coll Cardiol (Jan), 69(4): 367-377.
Bergsland N, Tavazzi E, LaganÃ MM, Baglio F, Cecconi P, Viotti S, Zivadinov R, Baselli G, Rovaris M. (2017) White Matter Tract Injury is Associated with Deep Gray Matter Iron Deposition in Multiple Sclerosis. J Neuroimaging (Jan), 27(1): 107-113.
Zivadinov R, Khan N, Medin J, Christoffersen P, Price J, Korn JR, Bonzani I, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B, Dwyer, III MG. (2017) An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study. J Neuroimaging (Jan), 27(3): 339-347.
Uher T, Vaneckova M, Sobisek L, Tyblova M, Seidl Z, Krasensky J, Ramasamy D, Zivadinov R, Havrdova E, Kalincik T, Horakova D. (2017) Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis. Mult Scler (Jan), 23(1): 51-61.
Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F. (2016) Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study. Radiology (Dec), 281(3): 884-895.
Zivadinov R, Khan N, Medin J, Christoffersen P, Price J, Korn JR, Bonzani I, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B. (2016) An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice-The MS-MRIUS Study. J Neuroimaging (Dec).
Sati P, Oh J, Constable RT, Evangelou N, Guttmann CR, Henry RG, Klawiter EC, Mainero C, Massacesi L, McFarland H, Nelson F, Ontaneda D, Rauscher A, Rooney WD, Samaraweera AP, Shinohara RT, Sobel RA, Solomon AJ, Treaba CA, Wuerfel J, Zivadinov R, Sicotte NL, Pelletier D, Reich DS. (2016) The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol (Dec), 12(12): 714-722.
Mokin M, Zivadinov R, Dwyer MG, Lazar RM, Hopkins LN, Siddiqui AH. (2016) Transcatheter aortic valve replacement: perioperative stroke and beyond. Expert Rev Neurother (Nov)1-8.
Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D. (2016) A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients. Mult Scler (Nov), 22(13): 1709-1718.
Roy S, Frndak S, Drake AS, Irwin L, Zivadinov R, Weinstock-Guttman B, Benedict RH. (2016) Differential effects of aging on motor and cognitive functioning in multiple sclerosis. Mult Scler (Nov).
Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B. (2016) Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study. Mult Scler (Nov).
Zivadinov R, Dwyer MG, Bergsland N. (2016) Brain atrophy measurements should be used to guide therapy monitoring in MS - YES. Mult Scler (Oct), 22(12): 1522-1524.
Roy S, Schwartz CE, Duberstein P, Dwyer MG, Zivadinov R, Bergsland N, Powell V, Weinstock-Guttman B, Benedict RH. (2016) Synergistic Effects of Reserve and Adaptive Personality in Multiple Sclerosis. J Int Neuropsychol Soc (Oct), 22(9): 920-927.
Gandhi S, Jakimovski D, Ahmed R, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R. (2016) Use of natalizumab in multiple sclerosis: current perspectives. Expert Opin Biol Ther (Sep), 16(9): 1151-1162.
Hagemeier J, Woodward MR, Rafique UA, Amrutkar CV, Bergsland N, Dwyer MG, Benedict R, Zivadinov R, Szigeti K. (2016) Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy. Psychiatry Res (Sep), 255: 87-93.
Bergsland N, Zivadinov R, Dwyer MG, Weinstock-Guttman B, Benedict RH. (2016) Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients. Mult Scler (Sep), 22(10): 1327-1336.
Mukhopadhyay S, Fellows K, Browne RW, Khare P, Krishnan Radhakrishnan S, Hagemeier J, Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2016) Interdependence of oxysterols with cholesterol profiles in multiple sclerosis. Mult Scler (Sep).
Khan O, Rieckmann P, Boyko A, Selmaj K, Ashtamker N, Davis MD, Kolodny S, Zivadinov R. (2016) Efficacy and safety of a three-times-weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 3-year results of the Glatiramer Acetate Low-Frequency Administration open-label extension study. Mult Scler (Aug).
Banwell B, Arnold DL, Tillema JM, Rocca MA, Filippi M, Weinstock-Guttman B, Zivadinov R, Sormani MP. (2016) MRI in the evaluation of pediatric multiple sclerosis. Neurology (Aug), 87(9 Sup): 88-96.
Haussig S, Mangner N, Dwyer MG, Lehmkuhl L, LÃ¼cke C, Woitek F, Holzhey DM, Mohr FW, Gutberlet M, Zivadinov R, Schuler G, Linke A. (2016) Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial. JAMA (Aug), 316(6): 592-601.
Schwartz CE, Dwyer MG, Benedict R, Weinstock-Guttman B, Bergsland NP, Li J, Ramanathan M, Zivadinov R. (2016) Reserve-related activities and MRI metrics in multiple sclerosis patients and healthy controls: an observational study. BMC Neurol (Jul), 16: 108-108.
Gupta S, Zivadinov R, Ramanathan M, Weinstock-Guttman B. (2016) Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?. Expert Rev Neurother (Jul), 16(7): 765-775.
Zivadinov R, Jakimovski D, Gandhi S, Ahmed R, Dwyer MG, Horakova D, Weinstock-Guttman B, Benedict RR, Vaneckova M, Barnett M, Bergsland N. (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother (Jul), 16(7): 777-793.
Zivadinov R, Cookfair DL, Krupp L, Miller AE, Lava N, Coyle PK, Goodman AD, Jubelt B, Lenihan M, Herbert J, Gottesman M, Snyder DH, Apatoff BR, Teter BE, Perel AB, Munschauer F, Weinstock-Guttman B. (2016) Factors associated with benign multiple sclerosis in the New York State MS Consortium (NYSMSC). BMC Neurol (Jul), 16: 102-102.
Beggs CB, Magnano C, Belov P, Krawiecki J, Ramasamy DP, Hagemeier J, Zivadinov R. (2016) Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients. PLoS One (May), 11(5): 0153960-0153960.
Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R. (2016) Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Mult Scler (May), 22(6): 770-781.
Sanai SA, Saini V, Benedict RH, Zivadinov R, Teter BE, Ramanathan M, Weinstock-Guttman B. (2016) Aging and multiple sclerosis. Mult Scler (May), 22(6): 717-725.
Beatty C, Bowler RA, Farooq O, Dudeck L, Ramasamy D, Yeh EA, Zivadinov R, Weinstock-Guttman B, Parrish JB. (2016) Long-Term Neurocognitive, Psychosocial, and Magnetic Resonance Imaging Outcomes in Pediatric-Onset Acute Disseminated Encephalomyelitis. Pediatr Neurol (Apr), 57: 64-73.
Roy S, Rodgers J, Drake AS, Zivadinov R, Weinstock-Guttman B, Benedict RH. (2016) Stable neuropsychiatric status in multiple sclerosis: a 3-year study. Mult Scler (Apr), 22(4): 569-574.
Greenberg SJ, Zivadinov R, Lee-Kwen P, Sharma J, Planter M, Umhauer M, Glenister N, Bakshi R. (2016) Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease. Ther Adv Neurol Disord (Mar), 9(2): 105-117.
Magnano C, Belov P, Krawiecki J, Hagemeier J, Beggs C, Zivadinov R. (2016) Internal Jugular Vein Cross-Sectional Area Enlargement Is Associated with Aging in Healthy Individuals. PLoS One (Feb), 11(2): 0149532-0149532.
Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, Weinstock-Guttman B, Ramanathan M. (2016) Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm (Feb), 3(1): 190-190.
Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R, Hojnacki DW. (2016) Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry (Feb), 87(2): 181-187.
Beggs CB, Magnano C, Shepherd SJ, Belov P, Ramasamy DP, Hagemeier J, Zivadinov R. (2016) Dirty-Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease. J Neuroimaging (Jan), 26(1): 136-143.
Modica CM, Bergsland N, Dwyer MG, Ramasamy DP, Carl E, Zivadinov R, Benedict RH. (2016) Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. Mult Scler (Jan), 22(1): 36-42.
Motl RW, Zivadinov R, Bergsland N, Benedict RH. (2016) Thalamus volume and ambulation in multiple sclerosis: a cross-sectional study. Neurodegener Dis Manag (Jan), 6(1): 23-29.
Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R, Hojnacki DW. (2016) Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. J Neurol Neurosurg Psychiatry (Jan).
Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S. (2015) Immunologic and MRI markers of the therapeutic effect of IFN-Î²-1a in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm (Dec), 2(6): 176-176.
Tao Y, Zhang X, Zivadinov R, Dwyer MG, Kennedy C, Bergsland N, Ramasamy D, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Markovic-Plese S, Hojnacki DW. (2015) Immunologic and MRI markers of the therapeutic effect of IFN-ß-1a in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm (Dec), 2(6): 176-176.
Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S, Hojnacki DW. (2015) Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial. BMC Neurol (Nov), 15: 232-232.
Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O. (2015) The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis. J Neuroimaging (Nov), 25(6): 989-995.
Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R, Ramanathan M. (2015) Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients. J Lipid Res (Oct), 56(10): 2010-2018.
Cesar B, Dwyer MG, Shucard JL, Polak P, Bergsland N, Benedict RH, Weinstock-Guttman B, Shucard DW, Zivadinov R. (2015) Cognitive and White Matter Tract Differences in MS and Diffuse Neuropsychiatric Systemic Lupus Erythematosus. AJNR Am J Neuroradiol (Oct), 36(10): 1874-1883.
Uher T, Horakova D, Tyblova M, Zeman D, Krasulova E, Mrazova K, Seidl Z, Vaneckova M, Krasensky J, Weinstock-Guttman B, Ramanathan M, Havrdova E, Zivadinov R. (2015) Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later. Mult Scler (Sep).
Mak E, Dwyer MG, Ramasamy DP, Au WL, Tan LC, Zivadinov R, Kandiah N. (2015) White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease. J Neuroimaging (Sep), 25(5): 754-760.
Schwartz CE, Ayandeh A, Ramanathan M, Benedict R, Dwyer MG, Weinstock-Guttman B, Zivadinov R. (2015) Reserve-building activities in multiple sclerosis patients and healthy controls: a descriptive study. BMC Neurol (Aug), 15: 135-135.
Fellows K, Uher T, Browne RW, Weinstock-Guttman B, Horakova D, Posova H, Vaneckova M, Seidl Z, Krasensky J, Tyblova M, Havrdova E, Zivadinov R, Ramanathan M. (2015) Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients. J Lipid Res (Aug).
Graziano E, Hagemeier J, Weinstock-Guttman B, Ramasamy DP, Zivadinov R. (2015) Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients. Neuroimage Clin (Aug), 9: 110-116.
Varosanec M, Uher T, Horakova D, Hagemeier J, Bergsland N, Tyblova M, Seidl Z, Vaneckova M, Krasensky J, Dwyer MG, Havrdova E, Zivadinov R. (2015) Longitudinal Mixed-Effect Model Analysis of the Association between Global and Tissue-Specific Brain Atrophy and Lesion Accumulation in Patients with Clinically Isolated Syndrome. AJNR Am J Neuroradiol (Aug), 36(8): 1457-1464.
Alexander JS, Chervenak R, Weinstock-Guttman B, Tsunoda I, Ramanathan M, Martinez N, Omura S, Sato F, Chaitanya GV, Minagar A, McGee J, Jennings MH, Monceaux C, Becker F, Cvek U, Trutschl M, Zivadinov R. (2015) Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. J Neurol Sci (Aug), 355(1-2): 84-89.
Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. (2015) Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon Î²-1a. Eur J Neurol (Jul), 22(7): 1113-1123.
Malyavantham K, Weinstock-Guttman B, Suresh L, Zivadinov R, Shanahan T, Badgett D, Ramanathan M. (2015) Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS One (Jun), 10(6): 0129503-0129503.
Narayanaswamy R, Iyer V, Khare P, Bodziak ML, Badgett D, Zivadinov R, Weinstock-Guttman B, Rideout TC, Ramanathan M, Browne RW. (2015) Simultaneous determination of oxysterols, cholesterol and 25-hydroxy-vitamin D3 in human plasma by LC-UV-MS. PLoS One (Apr), 10(4): 0123771-0123771.
Hagemeier J, Tong O, Dwyer MG, Schweser F, Ramanathan M, Zivadinov R. (2015) Effects of diet on brain iron levels among healthy individuals: an MRI pilot study. Neurobiol Aging (Apr), 36(4): 1678-1685.
Dwyer MG, Zivadinov R, Markovic-Plese S, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Weinstock-Guttman B, Hayward B, Dangond F. (2015) Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. J Neuroimmunol (Apr), 281: 44-50.
Zivadinov R, Dwyer M, Markovic-Plese S, Hayward B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Dangond F, Weinstock-Guttman B. (2015) A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (Mar), 8(2): 59-70.
Polak P, Leddy JJ, Dwyer MG, Willer B, Zivadinov R, Dwyer, III MG. (2015) Diffusion tensor imaging alterations in patients with postconcussion syndrome undergoing exercise treatment: a pilot longitudinal study. J Head Trauma Rehabil (Mar), 30(2): 32-42.
Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R. (2015) Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry (Feb).
Modica CM, Zivadinov R, Dwyer MG, Bergsland N, Weeks AR, Benedict RH, Dwyer, III MG. (2015) Iron and volume in the deep gray matter: association with cognitive impairment in multiple sclerosis. AJNR Am J Neuroradiol (Jan), 36(1): 57-62.
Mak E, Bergsland N, Dwyer MG, Zivadinov R, Kandiah N, Dwyer, III MG. (2014) Subcortical atrophy is associated with cognitive impairment in mild Parkinson disease: a combined investigation of volumetric changes, cortical thickness, and vertex-based shape analysis. AJNR Am J Neuroradiol (Dec), 35(12): 2257-2264.
Gupta S, Zivadinov R, Ramasamy D, Ambrus JL, Ambrus, Jr. JL. (2014) Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature. Clin Rheumatol (Dec), 33(12): 1829-1833.
Beggs CB, Magnano C, Shepherd SJ, Marr K, Valnarov V, Hojnacki D, Bergsland N, Belov P, Grisafi S, Dwyer MG, Carl E, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2014) Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. J Magn Reson Imaging (Nov), 40(5): 1215-1222.
Jacobsen, C, Hagemeier, J, Myhr, KM, Nyland, H, Lode, K, Bergsland, N, Ramasamy, D, Dalaker, TO, Larsen, JP, Farbu, E, Zivadinov R. (2014) Brain atrophy and disability progression in multiple sclerosis patients: A 10-year follow-up study. JNNP (Oct), 85(10): 1109-1115.
Uher T, Blahova-Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RH, Kalincik T, Ramasamy DP, Seidl Z, Hagermeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. (2014) Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome. J Neurol (Sep), 261(9): 1735-1744.
Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova, D, Bodziak, LM, Tamano-Blanco M, Badgett, D, Tyblova, M, Vaneckova, M, Seidl, Z, Krasensky, J, Qu, J, Havrdova E, Ramanathan M. (2014) Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. J Steroid Biochem (Sep), 143(9): 424-433.
Zivadinov R, Bergsland, N, Cappellani, R, Hagemeier, J, Melia, R, Carl, E, Dwyer MG, Lincoff NS, Weinstock-Guttman B, Ramanathan M. (2014) Retinal nerve fiber layer thickness and thalamus pathology in multiple sclerosis patients. Eur J Neurol (Aug), 21(8): 1137-1161.
Zivadinov R, Chin, J, Bergsland, N, Weinstock-Guttman B, Tamano-Blanco, M, Badgett, D, Hagemeier, J, Tyblova, M, Krasensky, J, Vaneckova, M, Seidl, M, Lelkova, P, Dwyer MG, Havrdova, E, Ramanathan M, Carl, E. (2014) Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. Neuroimmunol (Aug), 273(1-2): 58-64.
Browne RW, Horakova, D, Zivadinov R, Weinstock-Guttman B, Bodziak, LM, Tomano-Blanco, M, Badgett, D, Tyblova, M, Vaneckova, M, Seidl, Z, Krasensky, J, Bergsland, N, Ramasamy, D, Hagemeier, J, Havrdova, E, Ramanathan M. (2014) Apolipoproteins are associated with new MRI lesions and deep gray matter atrophy in clinically isolated syndromes. JNNP (Aug), 85(8): 859-864.
Barnett Y, Sutton IJ, Ghadiri M, Masters L, Zivadinov R, Barnett MH. (2014) Conventional and advanced imaging in neuromyelitis optica. Am J Neuroradiol (Aug), 35(8): 1458-1466.
Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML, Marr KL, Valnarov V, Kennedy CL, Ramanathan M, Ramasamy DP, Dolic K, Hojnacki DW, Carl E, Levy EI, Hopkins LN, Weinstock-Guttman B. (2014) Prospective randomized trial of venous angioplasty in MS (PREMiSe). Neurology (Jul), 83(5): 441-449.
Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E, Ramanathan M. (2014) Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study. J Steroid Biochem Mol Biol (Jun).
Cappellani, R, Bergsland, N, Weinstock-Guttman B, Kennedy, C, Carl, E, Ramasamy, D, Hagemeier, J, Dwyer MG, Patti, F, Zivadinov R. (2014) Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. J Neurol (Jun), 35(5): 912-919.
Modica CM, Zivadinov R, Dwyer MG, Bergsland N, Weeks AR, Benedict RH. (2014) Iron and Volume in the Deep Gray Matter: Association with Cognitive Impairment in Multiple Sclerosis. AJNR Am J Neuroradiol (Jun).
Goldberg H, Weinstock A, Bergsland N, Dwyer MG, Farooq O, Sazgar M, Poloni G, Treu C, Weinstock-Guttman B, Ramanathan M, Zivadinov R. (2014) MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurol (Jun), 14: 131-131.
Benedict RH, Morrow S, Rodgers J, Hojnacki D, Bucello MA, Zivadinov R, Weinstock-Guttman B. (2014) Characterizing cognitive function during relapse in multiple sclerosis. Mult Scler (May).
Cappellani, R, Bergsland, N, Weinstock-Guttman B, Kennedy, C, Carl, E, Ramasamy, D, Hagemeier, J, Dwyer MG, Patti, F, Zivadinov R. (2014) Subcortical deep gray matter pathology in multiple sclerosis patients is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor mri study. AJNR (May), 35(5): 912-919.
Polak P, Leddy JJ, Dwyer MG, Willer B, Zivadinov R. (2014) Diffusion Tensor Imaging Alterations in Patients With Postconcussion Syndrome Undergoing Exercise Treatment: A Pilot Longitudinal Study. J Head Trauma Rehabil (Apr).
Dwyer MG, Bergsland, N, Zivadinov R. (2014) Improved Longitudinal gray matter atrophy assessment via a combination of SIENA and a 4-demensional hidden Markov random field model. Neuroimage (Apr), 90(4): 207-217.
Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B, Hojnacki DW. (2014) Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study. PLoS One (Mar), 9(3): 91098-91098.
Zivadinov R, Markovic-Plese S,, Hussein, S, Kennedy, C, Bergsland, N, Ramasamy, D, Durfee, J, Hojnacki DW, Hayward, B, Dangond, F, Weinstock-Guttman B. (2014) Effect of interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis measured: a 24-week, controlled pilot study. PLoS One (Mar), 9(3).
Cappellani R, Bergsland N, Weinstock-Guttman B, Kennedy C, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Patti F, Zivadinov R, Dwyer, III MG. (2014) Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. J Neurol Sci (Mar), 338(1-2): 128-134.
Pfordresher, PQ, Mantell, JT, Brown, S, Zivadinov R, Cox J.L. (2014) Brain Responses to Altered Auditory Feedback During Musical Sequence Production; An fMRI study. Brain Res (Mar), 1556(3): 28-37.
Chung CP, Beggs, C, Wang, PN, Bergsland N, Shepherd, S, Cheng, CJ, Ramasamy, D, Dwyer MG, Hu, HH. (2014) Jugular venous reflux and periventricular white matter signal abnormalities in Alzheimer's Disease. J Alzh Dis (Mar), 39(3): 601-609.
Goldberg H, Weinstock A, Bergsland N, Dwyer MG, Farooq O, Sazgar M,Poloni G, Treu C, Weinstock-Guttman B, Ramanathan M and Zivadinov R. (2014) MRI segmentation analysis in temporal lobe and idiopathic generalized epilepsy. BMC Neurology (Jan), 14(131).
Donohue K, Cox JL, Dwyer MG, Aliotta R, Corwin M, Weinstock-Guttman B, Yeh EA, Zivadinov R. (2014) No Regional Gray Matter Atrophy Differences between Pediatric- and Adult-Onset Relapsing-Remitting Multiple Sclerosis. J Neuroimaging (Jan), 24(1): 63-67.
Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M. (2014) Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes. J Neurol Neurosurg Psychiatry (Jan).
Aliotta, R, Cox, JL, Donohue, K, Weinstock-Guttman B, Yeh, EA, Paul Polak, Dwyer MG, Zivadinov R. (2014) Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric and adult-onset multiple sclerosis. Hum Brain Mapp (Jan), 35(1): 53-60.
Zivadinov R, Gabelic, T, Ramasamy, DP, Weinstock-Guttman B, Hagemeier, J, Kennedy, C, Melia, R, Hojnacki DW, Ramanathan M. (2014) Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with familial multiple sclerosis. Am J Neuroradiol (Jan), 35(1): 106-112.
Gabelic T, Ramasamy DP, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Hojnacki D, Ramanathan M, Zivadinov R, Hojnacki DW. (2014) Prevalence of radiologically isolated syndrome and white matter signal abnormalities in healthy relatives of patients with multiple sclerosis. AJNR Am J Neuroradiol (Jan), 35(1): 106-112.
Gabelic T, Weinstock-Guttman B, Melia R, Lincoff N, Masud MW, Kennedy C, Brinar V, Ramasamy DP, Carl E, Bergsland N, Ramanathan M, Zivadinov R. (2013) Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. Clin Neurol Neurosurg (Dec), 115 S: 49-54.
Gupta S, Zivadinov R, Ramasamy DP, Ambrus J. (2013) Reversible cerebral vasoconstriction syndrome (RCVS) in antiphospholipid antibody syndrome (APLA): the role of centrally acting vasodilators. Case series and review of literature. Clinical Rheumatology (Nov).
Chitnits T, Gutmann Cr, Zaitsev A, Weinstock-Guttman B, Yeh E, Rodriguez M, Erickson B, Ness J, Gorman M. , Mussallam A. Healy BC, Kutz N, Chabas D, Strober JB, Waubant E, Pelletier D. Krupp L, Zivadinov R. (2013) Quantitative MR analysis in children with multiple sclerosis; A multicenter feasibility pilot study. BMC Neurology (Nov), 13(1).
Beggs, C, Magnano C, Shepherd SJ, Marr K, Valnarov V, Hojnacki D, Bergsland N, Belov P, Grisafi S, Dwyer MG, Carl E, Weinstock-Guttman B, Zivadinov R. (2013) Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. Journal of Magnetic Resonance Imaging (Nov).
Booth AJ, Rodgers JD, Schwartz CE, Quaranto BR, Weinstock-Guttman B, Zivadinov R, Benedict RH. (2013) Active cognitive reserve influences the regional atrophy to cognition link in multiple sclerosis. J Int Neuropsychol Soc (Nov), 19(10): 1128-1133.
Hagemeier J, Dwyer MG, Bergsland N, Schweser F, Magnano CR, Heininen-Brown M, Ramasamy DP, Carl E, Kennedy C, Melia R, Polak P, Deistung A, Geurts JJ, Reichenbach JR, Zivadinov R. (2013) Effect of age on MRI phase behavior in the subcortical deep gray matter of healthy individuals. AJNR Am J Neuroradiol (Nov), 34(11): 2144-2151.
Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G, Lakota E, O'Connor K, Badgett D, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Ramanathan M. (2013) Lipid profiles are associated with lesion formation over 24 months in interferon-ß treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (Nov), 84(11): 1186-1191.
Chung CP, Beggs C, Wang PN, Bergsland N, Shepherd S, Cheng CY, Ramasamy DP, Dwyer MG, Hu HH, Zivadinov R. (2013) Jugular Venous Reflux and White Matter Abnormalities in Alzheimer's Disease: A Pilot Study. J Alzheimers Dis (Nov).
Chung CP, Beggs C, Wang PN, Bergsland N, Shepherd S, Cheng CJ, Ramasamy DP, Dwyer MG, Hu HH, Zivadinov R. (2013) Jugular Venous Reflux and White Matter Abnormalities in Alzheimer‘s Disease: A Pilot Study. Journal of Alzheimer‘s Disease (Nov).
Zivadinov R, Karmon Y, Dolic K, Hagemeier J, Marr K, Valnarov V, Kennedy CL, Hojnacki D, Carl EM, Hopkins LN, Levy EI, Weinstock-Guttman B, Siddiqui AH, Siddiqui A. (2013) Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: results of the PREMiSe pilot study. BMC Neurol (Oct), 13: 151-151.
Zivadinov R, Karmon Y, Dolic K, Hagemeier J, Marr K, Valnarov V, Kennedy CL, Carl EM, Hopkins NL, Levy EI, Weinstock-Guttman B, Siddiqui AH. (2013) Multimodal noninvasive and invasive imaging of extra-cranial venous abnormalities indicative of CCSVI: Results of the PREMiSe study. BMC Neurology (Oct), 13(1).
Beggs C, Chung CP, Bergsland N, Wang PN, Shepherd S, Cheng CY, Dwyer MG, Hu HH, Zivadinov R. (2013) Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer‘s disease. BMC Neurol (Oct), 13(1): 157-157.
Beggs, C, Chung, CP, Bergsland, N, Wang, PN, Shepherd, S, Cheng, CJ, Dwyer M, Hu, HH, Zivadinov R. (2013) Jugular venous reflux and brain parenchyma volumes in elderly patients with mild cognitive impairment and Alzheimer‘s disease. BMC Neurology (Oct), 13.
Chaitanya GV, Omura S, Sato F, Martinez NE, Minagar A, Ramanathan M, Weinstock-Guttman B, Zivadinov R, Tsunoda I, Alexander JS. (2013) Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature. J Neuroinflamm (Oct), 10(1).
Zivadinov R, Treu CN, Weinstock-Guttman B, Turner C, Bergsland N, O‘Connor K, Dwyer MG, Carl E, Ramasamy DP, Qu J, Ramanathan M. (2013) Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (Oct), 84(10): 1075-1081.
Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Potts JA, Kalincik T, Havrdová E, Horáková D. (2013) Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. AJNR Am J Neuroradiol (Oct), 34(10): 1931-1939.
Zivadinov R, Bergsland N, Dolezal O, Hussein S, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Potts J, Kalincik, Havrdova E, Horkova D. (2013) Evolution of cortical and thalamus atrophy and disability progression in early RRMS over 5 years. AJNR (Oct)1931-1939.
Karmon, Y, Zivadinov R, Weinstock-Guttman B, Marr, K, Valnarov, V, Dolic, K, Kennedy, C, Hojnacki DW, Carl, E, Hagemeier, J, Hopkins, LN, Levy, EL, Siddiqui A. (2013) Comparison of intravascular ultrasound to catheter venography for the detection of extra-cranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. JVIR (Oct), 24.
Benedict RHB, Hulst HE, Bergland N, Schoonheim MM, Dwyer MG, Weinstock-Guttman B, Geurts JG, Zivadinov R. (2013) Clinical significance of atrophy and white mater mean diffusity with the thalamus of multiple sclerosis patients. Multiple Sclerosis (Oct), 19(11): 1478-1484.
Benedict RH, Hulst HE, Bergsland N, Schoonheim MM, Dwyer MG, Weinstock-Guttman B, Geurts JJ, Zivadinov R. (2013) Clinical significance of atrophy and white matter mean diffusivity within the thalamus of multiple sclerosis patients. Mult Scler (Oct), 19(11): 1478-1484.
Kardys A, Weinstock-Guttman B, Dillon M, Masud W, Weinstock N, Mahfooz N, Lang J, WEinstock A, Lincolff N, Zivadinov R, Ramanathan M. (2013) Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. European Journal of Neurology (Sep), 20(9): 1264-1271.
Kardys A, Weinstock-Guttman B, Dillon M, Masud MW, Weinstock N, Mahfooz N, Lang JK, Weinstock A, Lincoff N, Zivadinov R, Ramanathan M, Lincoff NS. (2013) Cholesterol affects retinal nerve fiber layer thickness in patients with multiple sclerosis with optic neuritis. Eur J Neurol (Sep), 20(9): 1264-1271.
Booth AJ, Rodgers JD, Schwartz CE, Quaranto BR, Weinstock-Guttman B, Zivadinov R, Benedict RHB. (2013) Active cognitive reserve influences the regional atrophy cognition link in multiple sclerosis. J Int Neuropsychol (Sep)1-6.
Wack DS, Dwyer MG, Bergsland N, Ramasamy D, Di Perri C, Ranza L, Hussein S, Magnano C, Seals K, Zivadinov R. (2013) Improved operator agreement and efficiency using the minimum area contour change method for delineation of hyperintense multiple sclerosis lesions on FLAIR MRI. BMC Med Imaging (Sep), 13(1): 29-29.
Zivadinov R, Havrdová E, Bergsland N, Tyblova M, Hagemeier J, Seidl Z, Dwyer MG, Vaneckova M, Krasensky J, Carl E, Kalincik T, Horáková D. (2013) Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology (Sep), 268(3): 831-841.
Zivadinov R, Havrdova, E, Bergsland, N, Tyblova, M, Hagemeier, J, Seidl, M, Dwyer M, Vaneckova, M, Krasensky, J, Kalincik, T, Horakova, D. (2013) Thalamic atrophy is associated with the development of clinically definite MS. Radiology (Sep), 268(3): 831-841.
Weinstock-Guttman B, Horakova, D, Zivadinov R, Tamano-Blanco, Badgett, D, Bergsland, N, Ramasamy, D, Hagemeier, J, Havrdova, E, Ramanathan, M. (2013) Interactions of serum cholesterol with anti-herpesvirus responses affect disease progression in clinically-isolated syndromes. Journal of Neuroimmunology (Aug), 263(1).
Tipirneni A, Weinstock-Guttman B, Ramanathan M, Abdelrahman N, Hussein S, Hagemeier J, Durfee J, Teter BE, Hojnacki D, Dwyer MG, Zivadinov R. (2013) MRI characteristics of familial and sporadic multiple sclerosis patients. Mult Scler (Aug), 19(9): 1145-1152.
Clifford, DB, Nath, A, Cinque, P, Brew, BJ, Zivadinov R, Gorelik, L, Zhao, Z, Duda, P. (2013) A study of mefloquine treatment for progressive multifocal leucoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirology (Aug), 19(4): 351-358.
Karmon Y, Zivadinov R, Weinstock-Guttman B, Marr K, Valnarov V, Dolic K, Kennedy CL, Hojnacki D, Carl EM, Hagemeier J, Hopkins LN, Levy EI, Siddiqui AH, Siddiqui A. (2013) Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. J Vasc Interv Radiol (Aug).
Benedict RHB, Weinstock-Guttman B, Valnarov V, Kennedy C, Carl E, Brooks C, Hojnacki D, Zivadinov R. (2013) Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis. BMC Med (Jul), 11(1).
Leddy JJ, Cox JL, Baker JG, Wack DS, Pendergast DR, Zivadinov R, Wiler B. (2013) Exercise treatment for post concussion syndrome: A pilot study of changes in functional magnetic resonance imaging activation, physiology and symptoms. J Head Trauma Rehabil (Jul), 28(4): 241-249.
Leddy JJ, Cox JL, Baker JG, Wack DS, Pendergast DR, Zivadinov R, Willer B. (2013) Exercise treatment for postconcussion syndrome: a pilot study of changes in functional magnetic resonance imaging activation, physiology, and symptoms. J Head Trauma Rehabil (Jul), 28(4): 241-249.
Zivadinov R, Weinstock-Guttman B. (2013) Funding CCSVI research is/was a waste of valuable time, money and intellectual energy; no. Multiple Sclerosis (Jun), 19(7): 858-860.
Weinstock-Guttman B, Zivadinov R, Horakova, D, Havrdova, E, Qu, J, Shyh, G, Lakota, E, O‘Connor, K, Badgett, D, Tamano-Blanco, M, Tyblova, M, Hussein, S, Bergsland, N, Willis, L, Krasensky, J, Vaneckova, M, Seidl, Z, Ramanathan M, Carl, E. (2013) Lipid profiles are associated with lesion formation over 24 months in interferon-b treated patients following the first demyelinating event. JNNP (Jun), 84: 1186-1191.
Zivadinov R, Shucard JL, Hussein S, Durfee J, Cox JL, Bergsland N, Dwyer MG, Benedict RH, Ambrus J, Shucard DW. (2013) Multimodal imaging in systemic lupus erythematosus patients with diffuse neuropsychiatric involvement. Lupus (Jun), 22(7): 675-683.
Zivadinov R, Shucard, DW, Hussein, S, Durfee, J, Cox, JL, Bergsland, N, Dwyer MG, Benedict RH, Shucard, J. (2013) Multimodal imaging manifestations of diffuse neuropsychiatric involvement in systemic lupus erythematosus. Lupus (Jun), 84: 1186-1191.
Zivadinov R, Magnano CR, Galeotti R, Schirda C, Menegatti E, Weinstock-Guttman B, Marr K, Bartolomei I, Hagemeier J, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Beggs C, Salvi F, Zamboni P. (2013) Changes of cine cerebrospinal fluid dynamics in multiple sclerosis patients treated wth percutaneous transluminla angioplasty: Case control study. JVIR (Jun), 24(6): 829-838.
Zivadinov R, Magnano C, Galeotti R, Schirda C, Menegatti E, Weinstock-Guttman B, Marr K, Bartolomei I, Hagemeier J, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Beggs C, Salvi F, Zamboni P, Hojnacki DW. (2013) Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. J Vasc Interv Radiol (Jun), 24(6): 829-838.
Dolic K, Siddiqui AH, Karmon Y, Marr K, Zivadinov R, Siddiqui A. (2013) The role of noninvasive and invasive diagnostic imaging techniques for detection of extra-cranial venous system anomalies and developmental variants. BMC Med (Jun), 11(1): 155-155.
Khan, O, Rieckmann, P, Boyko, A., Selmaj, K., Zivadinov R. (2013) Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Radiology (Jun), 73(6): 705-716.
Alves G, Pedersen KF, Bloem BR, Zetterberg H, Bronnick K, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP. (2013) Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. JNNP (May), 84(5): 537-543.
Schwendimann RN, Harris MK, Elliott DG, Menon U, Gonzalez-Toledo E, Zivadinov R, Pressly TA, Kelley RE, Hoque R, Fowler M, Maghzi AH, Etemadifar M, Saadatnia M, Minagar A. (2013) Neurosarcoidosis: Clinical Features, Diagnosis, and Management. Am J Neurotherap (May), 20(3): 292-299.
Hagemeier J, Yeh EA, Brown MH, Bergsland N, Dwyer MG, Carl E, Weinstock-Guttman B, Zivadinov R. (2013) Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. Mult Scler (Apr), 19(5): 567-576.
Benedict RH, Schwartz CE, Duberstein P, Healy B, Hoogs M, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R. (2013) Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis. Psychosom Med (Apr), 75(3): 253-261.
Kardys A, Weinstock-Guttman B, Dillon M, Masud M, Weinstock N, Mahfooz N, Lang J, Weinstock A, Lincoff N, Zivadinov R, Ramanathan, M. (2013) Cholesterol Affects Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis Patients with Optic Neuritis. European Journal of Neurology (Apr), 20(9): 1264-1271.
Zivadinov R, Tekwe C, Bergsland N, Dolezal O, Havrdova E, Krasensky J, Dwyer MG, Seidl Z, Ramasamy DP, Vaneckova M, Horakova D. (2013) Bi-monthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years; A longitudinal study. Multiple Sclerosis International (Feb), 2013.
Zivadinov R, Tekwe C, Bergsland N, Dolezal O, Havrdova E, Krasensky J, Dwyer MG, Seidl Z, Ramasamy DP, Vaneckova M, Horakova D. (2013) Bimonthly Evolution of Cortical Atrophy in Early Relapsing-Remitting Multiple Sclerosis over 2 Years: A Longitudinal Study. Mult Scler Int (Jan), 2013: 231345-231345.
Hagemeier J, Weinstock-Guttman B, Heininen-Brown M, Poloni GU, Bergsland N, Schirda C, Magnano CR, Kennedy C, Carl E, Dwyer MG, Minagar A, Zivadinov R. (2013) Gray matter SWI-filtered phase and atrophy are linked to disability in MS. Front Biosci (Elite Ed) (Jan), 5: 525-532.
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Quj, Tamano Blanco M, Badgett D, Tyblova M. Berglsand N, Hussein S. Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Kalincik T, Ramanathan M. (2013) Environmental factors associated with disease progression after the first demyelinating event: Results from the multi-center SET study. PLos One (Jan), 8(1).
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamaño-Blanco M, Badgett D, Tyblova M, Bergsland N, Hussein S, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Dwyer MG, Zhang M, Yu H, Duan X, Kalincik T, Ramanathan M. (2013) Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (Jan), 8(1): 53996-53996.
Chung CH, Cheng CY, Zivadinov R, Chen WC, Sheng WY, Lee YC, Hu HH, Hsu HY, Yang KY. (2013) Jugular venous reflux and plasma endothelin-1 are associated with cough syncope: a case control pilot study. BMC Neurology (Jan), 13.
Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. (2013) The thalamus and multiple sclerosis: modern views on pathologic, imaging and clinical aspects. Neurology (Jan), 80(2).
Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. (2013) The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology (Jan), 80(2): 210-219.
Hagemeier J, Geurts JJG, Zivadinov R. (2012) Brain iron accumulation in aging and neurodegenerative disorders. Expert Rev Neurother (Dec), 12(12): 1467-1480.
Zivadinov R., Cutter G, Marr K, Ramanathan M, Benedict RHB, Elfadil M, Bergsland N, Morgan C, Carl E, Hojnacki D, Yeh AE, Willis A, Cherneva M, Hussein S, Durfee J, Kennedy C, Dwyer MG, Weinstock-Guttman B. (2012) No association between conventional brain MRI and CCSVI in multiple sclerosis. Am J Neuroradiol (Nov), 33(10): 1913-1917.
Dolic K, Weinstock-Guttman B, Marr K, Valnarov V, Carl E, Hagemeier J, Kennedy C, Kilanowski C, Hojnacki D, Ramanathan M, Zivadinov R, Hojnacki DW. (2012) Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. Neurol Res (Oct), 34(8): 819-827.
Karmon Y, Ramanathan M, Minagar A, Zivadinov R, Weinstock-Guttman B. (2012) Arterial, venous and other vascular risk factors in multiple sclerosis. Neurol Res (Oct), 34(8): 754-760.
Zivadinov R, Ramanathan M, Ambrus J, Hussein S, Ramasamy DP, Dwyer MG, Bergsland N, Minagar A, Weinstock-Guttman B. (2012) Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study. Neurol Res (Oct), 34(8): 761-769.
Magnano C, Schirda C, Weinstock-Guttman B, Wack DS, Lindzen E, Hojnacki D, Bergsland N, Kennedy C, Belov P, Dwyer MG, Poloni GU, Beggs CB, Zivadinov R. (2012) Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging (Oct), 36(4): 825-834.
Beggs CB, Shepherd SJ, Dwyer MG, Polak P, Magnano C, Carl E, Poloni GU, Weinstock-Guttman B, Zivadinov R. (2012) Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. Neurol Res (Oct), 34(8): 793-801.
Bergsland N, Horakova D, Dwyer MG, Dolezal O, Seidl ZK, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R. (2012) Subcortical and cortical gray matter atrophy in a large sample of patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol (Sep), 33(8): 1573-1578.
Hagemeier J, Weinstock-Guttman B, Bergsland N, Heininen-Brown M, Carl E, Kennedy C, Magnano C, Hojnacki D, Dwyer MG, Zivadinov R. (2012) Iron deposition on SWI-filtered phase in the subcortical deep gray matter of patients with clinically isolated syndrome may precede structure-specific atrophy. AJNR Am J Neuroradiol (Sep), 33(8): 1596-1601.
Aliotta R, Cox JL, Donohue K, Weinstock-Guttman B, Yeh EA, Polak P, Dwyer M, Zivadinov R. (2012) Tract-based spatial statistics analysis of diffusion-tensor imaging data in pediatric- and adult-onset multiple sclerosis. Hum Brain Mapp (Aug).
Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B. (2012) Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNß-1a in multiple sclerosis. Mult Scler (Aug), 18(8): 1125-1134.
Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B, Hojnacki DW. (2012) Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNÎ²-1a in multiple sclerosis. Mult Scler (Aug), 18(8): 1125-1134.
Hagemeier J, Heininen-Brown M, Poloni GU, Bergsland N, Magnano CR, Durfee J, Kennedy C, Carl E, Weinstock-Guttman B, Dwyer MG, Zivadinov R. (2012) Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging (Jul), 36(1): 73-83.
Weinstock-Guttman B, Ramanathan M, Marr K, Hojnacki D, Benedict RH, Morgan C, Yeh EA, Carl E, Kennedy C, Reuther J, Brooks C, Hunt K, Elfadil M, Andrews M, Zivadinov R. (2012) Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurol (May), 12: 26-26.
Zivadinov R, Hojnacki D, Hussein S, Bergsland N, Carl E, Durfee J, Dwyer MG, Kennedy C, Weinstock-Guttman B. (2012) Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. Int J Mol Sci (May), 13(5): 5659-5673.
Zivadinov R, Cutter G, Marr K, Ramanathan M, Benedict RH, Bergsland N, Morgan C, Carl E, Hojnacki D, Yeh EA, Willis L, Cherneva M, Kennedy C, Dwyer MG, Weinstock-Guttman B. (2012) No Association Between Conventional Brain MR Imaging and Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis. AJNR Am J Neuroradiol (May).
Livshits I, Hussein S, Kennedy C, Weinstock-Guttman B, Hojnacki D, Zivadinov R, Hojnacki DW. (2012) Comparison of a 1.5T standard vs. 3T optimized protocols in multiple sclerosis patients. Minerva Med (Apr), 103(2): 97-102.
O'Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan M. (2012) Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol (Apr), 259(4): 637-644.
Foster M, Zivadinov R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Carl E, Ramanathan M. (2012) Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (Feb), 243(1-2): 61-68.
Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer MG, Weinstock-Guttman B, Benedict RH. (2012) Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (Jan), 259(1): 139-146.
Zivadinov R, Heininen-Brown M, Schirda CV, Poloni GU, Bergsland N, Magnano CR, Durfee J, Kennedy C, Carl E, Hagemeier J, Benedict RH, Weinstock-Guttman B, Dwyer MG. (2012) Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (Jan), 59(1): 331-339.
Zivadinov R, Hussein S, Bergsland N, Minagar A, Dwyer MG. (2012) Magnetization transfer imaging of acute black holes in patients on glatiramer acetate. Front Biosci (Elite Ed) (Jan), 4: 1496-1504.
Dolic K, Marr K, Valnarov V, Dwyer MG, Carl E, Karmon Y, Kennedy C, Brooks C, Kilanowski C, Hunt K, Siddiqui AH, Hojnacki D, Weinstock-Guttman B, Zivadinov R, Hojnacki DW. (2012) Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by 2 noninvasive imaging techniques. AJNR Am J Neuroradiol (Jan), 33(1): 16-23.
Wack DS, Dwyer MG, Bergsland, N, Di Perri, C, Ranza, l, Hussein, S, Ramasamy, D, Poloni, G, Zivadinov R. (2012) Improved assessment of multiple sclerosis lesion segmentation agreement via detection and outline error estimates. BMC Medical Imaging (Jan), 12(17).
Covey TJ, Zivadinov R, Shucard JL, Shucard DW. (2011) Information processing speed, neural efficiency, and working memory performance in multiple sclerosis: Differential relationships with structural magnetic resonance imaging. J Clin Exp Neuropsychol (Dec), 33(10): 1129-1145.
Weinstock-Guttman B, Zivadinov R, Ramanathan M. (2011) Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci (Dec), 311(1-2): 86-91.
Polak P, Magnano C, Zivadinov R, Poloni G. (2011) 3D FLAIRED: 3D fluid attenuated inversion recovery for enhanced detection of lesions in multiple sclerosis. Magn Reson Med (Dec).
Zivadinov R, Dwyer M, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B, Hojnacki DW. (2011) Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNß-1a in multiple sclerosis. Mult Scler (Dec).
Dolic K, Weinstock-Guttman B, Marr K, Valnarov V, Carl E, Hagemeier J, Brooks C, Kilanowski C, Hojnacki D, Ramanathan M, Zivadinov R. (2011) Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. PLoS One (Nov), 6(11): 28062-28062.
Habib CA, Liu M, Bawany N, Garbern J, Krumbein I, Mentzel HJ, Reichenbach J, Magnano C, Zivadinov R, Haacke EM. (2011) Assessing Abnormal Iron Content in the Deep Gray Matter of Patients with Multiple Sclerosis versus Healthy Controls. AJNR Am J Neuroradiol (Nov).
Covey TJ, Zivadinov, R, Shucard, JL, Shucard, DW. (2011) Information processing speed, neural efficiency, and working memory performance in Multiple Sclerosis: Differential relationships with structural MRI. Journal of Clinical and Experimental Neuropsychology (Nov), 33(10): 1129-1145.
Zivadinov R, Poloni GU, Marr K, Schirda CV, Magnano CR, Carl E, Bergsland N, Hojnacki D, Kennedy C, Beggs CB, Dwyer MG, Weinstock-Guttman B. (2011) Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurol (Oct), 11: 128-128.
Dolic K, Marr K, Valnarov V, Dwyer MG, Carl E, Hagemeier J, Kennedy C, Brooks C, Kilanowski C, Hunt K, Hojnacki D, Weinstock-Guttman B, Zivadinov R. (2011) Sensitivity and specificity for screening of chronic cerebrospinal venous insufficiency using a multimodal non-invasive imaging approach in patients with multiple sclerosis. Funct Neurol (Oct), 26(4): 205-214.
Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, Teter B, Hussein S, Mehta B, Weiskopf M, Durfee J, Bergsland N, Ramanathan M. (2011) Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (Oct), 8.
O'Connor K, Weinstock-Guttman B, Carl E, Kilanowski C, Zivadinov R, Ramanathan M. (2011) Patterns of dietary and herbal supplement use by multiple sclerosis patients. J Neurol (Sep).
Zivadinov R, Ramanathan M, Dolic K, Marr K, Karmon Y, Siddiqui AH, Benedict RH, Weinstock-Guttman B. (2011) Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother (Sep), 11(9): 1277-1294.
Zamboni P, Galeotti R, Weinstock-Guttman B, Kennedy C, Salvi F, Zivadinov R. (2011) Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study. Eur J Vasc Endovasc Surg (Aug).
Poloni G, Minagar A, Haacke EM, Zivadinov R. (2011) Recent developments in imaging of multiple sclerosis. Neurologist (Jul), 17(4): 185-204.
Antulov R, Carone DA, Bruce J, Yella V, Dwyer MG, Tjoa CW, Benedict RH, Zivadinov R. (2011) Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. J Neuroimaging (Jul), 21(3): 210-218.
Batista S, Zivadinov R, Hoogs M, Bergsland N, Heininen-Brown M, Dwyer M, Weinstock-Guttman B, Benedict RH. (2011) Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (Jul).
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Tamaño-Blanco M, Tyblova M, Hussein S, Bergsland N, Willis L, Krasensky J, Vaneckova M, Seidl Z, Lelkova P, Ramanathan M. (2011) HLA DRB1*1501 is only modestly associated with lesion burden at the first demyelinating event. J Neuroimmunol (Jul), 236(1-2): 76-80.
Mokin M, Kass-Hout T, Kass-Hout O, Zivadinov R, Mehta B. (2011) Blood Pressure Management and Evolution of Thrombolysis-associated Intracerebral Hemorrhage in Acute Ischemic Stroke. J Stroke Cerebrovasc Dis (Jun).
Benedict RH, Zivadinov R. (2011) Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol (Jun), 7(6): 332-342.
Valerio M, Liu HB, Heffner R, Zivadinov R, Ramanathan M, Weinstock-Guttman B, Awad AB. (2011) Phytosterols ameliorate clinical manifestations and inflammation in experimental autoimmune encephalomyelitis. Inflamm Res (May), 60(5): 457-465.
Zivadinov R, Marr K, Cutter G, Ramanathan M, Benedict RH, Kennedy C, Elfadil M, Yeh AE, Reuther J, Brooks C, Hunt K, Andrews M, Carl E, Dwyer MG, Hojnacki D, Weinstock-Guttman B, Yeh E. (2011) Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology (Apr).
Zivadinov R, Galeotti R, Hojnacki D, Menegatti E, Dwyer MG, Schirda C, Malagoni AM, Marr K, Kennedy C, Bartolomei I, Magnano C, Salvi F, Weinstock-Guttman B, Zamboni P. (2011) Value of MR Venography for Detection of Internal Jugular Vein Anomalies in Multiple Sclerosis: A Pilot Longitudinal Study. AJNR Am J Neuroradiol (Apr).
Zamboni P, Menegatti E, Weinstock-Guttman B, Dwyer MG, Schirda CV, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Bergsland N, Magnano C, Bartolomei I, Salvi F, Zivadinov R. (2011) Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. BMC Med (Mar), 9: 22-22.
Weinstock-Guttman B, Zivadinov R, Cutter G, Tamaño-Blanco M, Marr K, Badgett D, Carl E, Elfadil M, Kennedy C, Benedict RH, Ramanathan M. (2011) Chronic cerebrospinal vascular insufficiency is not associated with HLA DRB1*1501 status in multiple sclerosis patients. PLoS One (Feb), 6(2): 16802-16802.
Ramasamy DP, Ramanathan M, Cox JL, Antulov R, Weinstock-Guttman B, Bergsland N, Benedict RH, Dwyer MG, Minagar A, Zivadinov R. (2011) Effect of Met66 allele of the BDNF rs6265 SNP on regional gray matter volumes in patients with multiple sclerosis: A voxel-based morphometry study. Pathophysiology (Feb), 18(1): 53-60.
Zivadinov R, Hussein S, Stosic M, Durfee J, Cox JL, Cookfair DL, Hashmi K, Abdelrahman N, Garg N, Dwyer MG, Weinstock-Guttman B. (2011) Glatiramer acetate recovers microscopic tissue damage in patients with multiple sclerosis. A case-control diffusion imaging study. Pathophysiology (Feb), 18(1): 61-68.
Alexander JS, Zivadinov R, Maghzi AH, Ganta VC, Harris MK, Minagar A. (2011) Multiple sclerosis and cerebral endothelial dysfunction: Mechanisms. Pathophysiology (Feb), 18(1): 3-12.
Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS, Tysnes OB, Aarsland D, Larsen JP. (2011) Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord (Feb), 26(2): 297-301.
Zivadinov R, Lopez-Soriano A, Weinstock-Guttman B, Schirda CV, Magnano CR, Dolic K, Kennedy CL, Brooks CL, Reuther JA, Hunt K, Andrews M, Dwyer MG, Hojnacki DW. (2011) Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology (Feb), 258(2): 562-570.
Weinstock-Guttman B, Zivadinov R, Qu J, Cookfair D, Duan X, Bang E, Bergsland N, Hussein S, Cherneva M, Willis L, Heininen-Brown M, Ramanathan M. (2011) Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (Feb), 82(2): 189-195.
Weinstock-Guttman B, Benedict RH, Tamaño-Blanco M, Ramasamy DP, Stosic M, Polito J, Zivadinov R, Ramanathan M. (2011) The rs2030324 SNP of brain-derived neurotrophic factor (BDNF) is associated with visual cognitive processing in multiple sclerosis. Pathophysiology (Feb), 18(1): 43-52.
Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS, Tysnes OB, Aarsland D, Larsen JP. (2010) Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. Mov Disord (Dec).
Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict RH. (2010) Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (Oct), 24(7): 1131-1145.
Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J. (2010) Rapid disease course in African Americans with multiple sclerosis. Neurology (Jul), 75(3): 217-223.
Antulov R, Carone DA, Bruce J, Yella V, Dwyer M, Tjoa CW, Benedict RH, Zivadinov R. (2010) Regionally Distinct White Matter Lesions Do Not Contribute to Regional Gray Matter Atrophy in Patients with Multiple Sclerosis. J Neuroimaging (Apr).
Hojnacki D, Zamboni P, Lopez-Soriano A, Galleotti R, Menegatti E, Weinstock-Guttman B, Schirda C, Magnano C, Malagoni AM, Kennedy C, Bartolomei I, Salvi F, Zivadinov R. (2010) Use of neck magnetic resonance venography, Doppler sonography and selective venography for diagnosis of chronic cerebrospinal venous insufficiency: a pilot study in multiple sclerosis patients and healthy controls. Int Angiol (Apr), 29(2): 127-139.
Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, Bronnick K, Tysnes OB, Antulov R, Dwyer M, Aarsland D. (2010) Gray matter correlations of cognition in incident Parkinson's disease. Mov Disord (Apr), 25(5): 629-633.
Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, Bronnick K, Tysnes OB, Antulov R, Dwyer MG, Aarsland D. (2010) Gray matter correlations of cognition in incident Parkinson‘s disease. Mov Disord (Apr), 25(5): 629-633.
Zamboni P, Menegatti E, Weinstock-Guttman B, Schirda C, Cox JL, Malagoni AM, Hojnacki D, Kennedy C, Carl E, Dwyer MG, Bergsland N, Galeotti R, Hussein S, Bartolomei I, Salvi F, Ramanathan M, Zivadinov R. (2010) CSF dynamics and brain volume in multiple sclerosis are associated with extracranial venous flow anomalies: a pilot study. Int Angiol (Apr), 29(2): 140-148.
Zivadinov R, Schirda C, Dwyer MG, Haacke ME, Weinstock-Guttman B, Menegatti E, Heininen-Brown M, Magnano C, Malagoni AM, Wack DS, Hojnacki D, Kennedy C, Carl E, Bergsland N, Hussein S, Poloni G, Bartolomei I, Salvi F, Zamboni P. (2010) Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. Int Angiol (Apr), 29(2): 158-175.
Minagar A, Alexander JS, Sahraian MA, Zivadinov R. (2010) Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther (Mar), 10(3): 421-429.
Horstman LL, Jy W, Ahn YS, Zivadinov R, Maghzi AH, Etemadifar M, Steven Alexander J, Minagar A. (2010) Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (Feb), 7: 10-10.
Weinstock-Guttman B, Ramanathan M, Hashmi K, Abdelrahman N, Hojnacki D, Dwyer MG, Hussein S, Bergsland N, Munschauer FE, Zivadinov R. (2010) Increased tissue damage and lesion volumes in African Americans with multiple sclerosis. Neurology (Feb), 74(7): 538-544.
Stosic M, Ambrus J, Garg N, Weinstock-Guttman B, Ramanathan M, Kalman B, Minagar A, Munschauer FE, Galey TM, Hussein S, Bakshi R, Zivadinov R. (2010) MRI characteristics of patients with antiphospholipid syndrome and multiple sclerosis. J Neurol (Jan), 257(1): 63-71.
Frohman EM, Cutter G, Remington G, Gao H, Rossman H, Weinstock-Guttman B, Durfee JE, Conger A, Carl E, Treadaway K, Lindzen E, Salter A, Frohman TC, Shah A, Bates A, Cox JL, Dwyer MG, Stüve O, Greenberg BM, Racke MK, Zivadinov R. (2010) A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (Jan), 3(1): 15-28.
Horáková D, Kýr M, Havrdová E, Doležal O, Lelková P, Pospíšilová L, Bergsland N, Dwyer MG, Cox JL, Hussein S, Seidl Z, Vanecková M, Krásenský J, Zivadinov R. (2010) Apolipoprotein E e4-Positive multiple sclerosis patients develop more gray-matter and whole-brain atrophy: a 15-year disease history model based on a 4-year longitudinal study. Folia Biol (Praha) (Jan), 56(6): 242-251.
Yeh EA, Weinstock-Guttman B, Ramanathan M, Ramasamy DP, Willis L, Cox JL, Zivadinov R. (2009) Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. Brain (Dec), 132(Pt 12): 3392-3400.
Dalaker TO, Larsen JP, Bergsland N, Beyer MK, Alves G, Dwyer MG, Tysnes OB, Benedict RH, Kelemen A, Bronnick K, Zivadinov R. (2009) Brain atrophy and white matter hyperintensities in early Parkinson's disease(a). Mov Disord (Nov), 24(15): 2233-2241.
Dalaker TO, Larsen JP, Dwyer MG, Aarsland D, Beyer MK, Alves G, Bronnick K, Tysnes OB, Zivadinov R. (2009) White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. Neuroimage (Oct), 47(4): 2083-2089.
Di Perri C, Dwyer MG, Wack DS, Cox JL, Hashmi K, Saluste E, Hussein S, Schirda C, Stosic M, Durfee J, Poloni GU, Nayyar N, Bergamaschi R, Zivadinov R. (2009) Signal abnormalities on 1.5 and 3 Tesla brain MRI in multiple sclerosis patients and healthy controls. A morphological and spatial quantitative comparison study. Neuroimage (Oct), 47(4): 1352-1362.
Zivadinov R, Weinstock-Guttman B, Hashmi K, Abdelrahman N, Stosic M, Dwyer M, Hussein S, Durfee J, Ramanathan M. (2009) Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology (Aug), 73(7): 504-510.
Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D. (2009) Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis. Mult Scler (Aug), 15(8): 965-976.
Frohman EM, Dwyer MG, Frohman T, Cox JL, Salter A, Greenberg BM, Hussein S, Conger A, Calabresi P, Balcer LJ, Zivadinov R. (2009) Relationship of optic nerve and brain conventional and non-conventional MRI measures and retinal nerve fiber layer thickness, as assessed by OCT and GDx: a pilot study. J Neurol Sci (Jul), 282(1-2): 96-105.
Zamboni P, Menegatti E, Weinstock-Guttman B, Schirda C, Cox JL, Malagoni AM, Hojanacki D, Kennedy C, Carl E, Dwyer MG, Bergsland N, Galeotti R, Hussein S, Bartolomei I, Salvi F, Zivadinov R. (2009) The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Funct Neurol (Jul), 24(3): 133-138.
Dwyer M, Bergsland N, Hussein S, Durfee J, Wack D, Zivadinov R, Wack DS. (2009) A sensitive, noise-resistant method for identifying focal demyelination and remyelination in patients with multiple sclerosis via voxel-wise changes in magnetization transfer ratio. J Neurol Sci (Jul), 282(1-2): 86-95.
Geurts JJ, Stys PK, Minagar A, Amor S, Zivadinov R. (2009) Gray matter pathology in (chronic) MS: modern views on an early observation. J Neurol Sci (Jul), 282(1-2): 12-20.
Horakova D, Dwyer MG, Havrdova E, Cox JL, Dolezal O, Bergsland N, Rimes B, Seidl Z, Vaneckova M, Zivadinov R. (2009) Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis: a 5-year longitudinal study. J Neurol Sci (Jul), 282(1-2): 112-119.
Ramasamy DP, Benedict RH, Cox JL, Fritz D, Abdelrahman N, Hussein S, Minagar A, Dwyer MG, Zivadinov R. (2009) Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (Jul), 282(1-2): 47-54.
Zivadinov R, Minagar A. (2009) Evidence for gray matter pathology in multiple sclerosis: a neuroimaging approach. J Neurol Sci (Jul), 282(1-2): 1-4.
Zivadinov R, Zorzon M, Weinstock-Guttman B, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M. (2009) Epstein-Barr virus is associated with grey matter atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry (Jun), 80(6): 620-625.
Zivadinov R, Weinstock-Guttman B, Zorzon M, Uxa L, Serafin M, Bosco A, Bratina A, Maggiore C, Grop A, Tommasi MA, Srinivasaraghavan B, Ramanathan M. (2009) Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol (Apr), 209(1-2): 123-130.
Salter AR, Conger A, Frohman TC, Zivadinov R, Eggenberger E, Calabresi P, Cutter G, Balcer L, Frohman EM. (2009) Retinal architecture predicts pupillary reflex metrics in MS. Mult Scler (Apr), 15(4): 479-486.
Antulov R, Weinstock-Guttman B, Cox JL, Hussein S, Durfee J, Caiola C, Dwyer MG, Bergsland N, Abdelrahman N, Stosic M, Hojnacki D, Munschauer FE, Miletic D, Zivadinov R. (2009) Gender-related differences in MS: a study of conventional and nonconventional MRI measures. Mult Scler (Mar), 15(3): 345-354.
Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. (2009) Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol Neurosurg Psychiatry (Feb), 80(2): 201-206.
Horstman LL, Jy W, Bidot CJ, Ahn YS, Kelley RE, Zivadinov R, Maghzi AH, Etemadifar M, Mousavi SA, Minagar A. (2009) Antiphospholipid antibodies: paradigm in transition. J Neuroinflammation (Jan), 6: 3-3.
Zivadinov R. (2009) Advanced magnetic resonance imaging metrics: implications for multiple sclerosis clinical trials. Methods Find Exp Clin Pharmacol (Jan), 31(1): 29-40.
Di Perri C, Dalaker TO, Beyer MK, Zivadinov R. (2009) Neuroimaging of cognitive impairments in vascular disease. Int Rev Neurobiol (Jan), 84: 49-80.
Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. (2008) Memory Impairment in Multiple Sclerosis: Correlation with Deep Gray Matter and Mesial Temporal Atrophy. J Neurol Neurosurg Psychiatry (Oct).
Dwyer MG, Bergsland N, Saluste E, Sharma J, Jaisani Z, Durfee J, Abdelrahman N, Minagar A, Hoque R, Munschauer FE, Zivadinov R. (2008) Application of hidden Markov random field approach for quantification of perfusion/diffusion mismatch in acute ischemic stroke. Neurol Res (Oct), 30(8): 827-834.
Zivadinov R, Bergsland N, Stosic M, Sharma J, Nussenbaum F, Durfee J, Hani N, Abdelrahman N, Jaisani Z, Minagar A, Hoque R, Munschauer FE, Dwyer MG. (2008) Use of perfusion- and diffusion-weighted imaging in differential diagnosis of acute and chronic ischemic stroke and multiple sclerosis. Neurol Res (Oct), 30(8): 816-826.
Weinstock-Guttman B, Miller C, Yeh E, Stosic M, Umhauer M, Batra N, Munschauer F, Zivadinov R, Ramanathan M. (2008) Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult Scler (Sep), 14(8): 1061-1067.
Weinstock-Guttman B, Ramanathan M, Zivadinov R. (2008) Interferon-beta treatment for relapsing multiple sclerosis. Expert Opin Biol Ther (Sep), 8(9): 1435-1447.
Zivadinov R, Munschauer FE, Ramanathan M, Benedict RH, Weinstock-Guttman B. (2008) Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Drugs Today (Barc) (Aug), 44(8): 601-613.
Benedict RH, Hussein S, Englert J, Dwyer MG, Abdelrahman N, Cox JL, Munschauer FE, Weinstock-Guttman B, Zivadinov R. (2008) Cortical atrophy and personality in multiple sclerosis. Neuropsychology (Jul), 22(4): 432-441.
Zivadinov R, Reder AT, Filippi M, Minagar A, Stüve O, Lassmann H, Racke MK, Dwyer MG, Frohman EM, Khan O. (2008) Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology (Jul), 71(2): 136-144.
Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E, Munschauer F. (2008) Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler (Jul), 14(6): 759-763.
Benedict RH, Shucard JL, Zivadinov R, Shucard DW. (2008) Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis. Neuropsychol Rev (Jun), 18(2): 149-166.
Benedict RH, Shucard JL, Zivadinov R, Shucard DW. (2008) Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis. Neuropsychol Rev (Jun), 18(2): 149-166.
Grazioli E, Zivadinov R, Weinstock-Guttman B, Lincoff N, Baier M, Wong JR, Hussein S, Cox JL, Hojnacki D, Ramanathan M. (2008) Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (May), 268(1-2): 12-17.
Tjoa CW, Benedict RH, Dwyer MG, Carone DA, Zivadinov R. (2008) Regional specificity of magnetization transfer imaging in multiple sclerosis. J Neuroimaging (Apr), 18(2): 130-136.
Horakova D, Cox JL, Havrdova E, Hussein S, Dolezal O, Cookfair D, Dwyer MG, Seidl Z, Bergsland N, Vaneckova M, Zivadinov R. (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years: a case-control study. J Neurol Neurosurg Psychiatry (Apr), 79(4): 407-414.
Zivadinov R, Zorzon M, De Masi R, Nasuelli D, Cazzato G. (2008) Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis. J Neurol Sci (Apr), 267(1-2): 28-35.
Zivadinov R, Stosic M, Cox JL, Ramasamy DP, Dwyer MG. (2008) The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol (Mar), 255 S: 61-74.
Zivadinov R, Banas AC, Yella V, Abdelrahman N, Weinstock-Guttman B, Dwyer MG. (2008) Comparison of three different methods for measurement of cervical cord atrophy in multiple sclerosis. AJNR Am J Neuroradiol (Feb), 29(2): 319-325.
Brass SD, Zivadinov R, Bakshi R. (2008) Acute demyelinating optic neuritis: a review. Front Biosci (Jan), 13: 2376-2390.
Frohman EM, Costello F, Stüve O, Calabresi P, Miller DH, Hickman SJ, Sergott R, Conger A, Salter A, Krumwiede KH, Frohman TC, Balcer L, Zivadinov R. (2008) Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis. Arch Neurol (Jan), 65(1): 26-35.
Stüve O, Bennett JL, Hemmer B, Wiendl H, Racke MK, Bar-Or A, Hu W, Zivadinov R, Weber MS, Zamvil SS, Pacheco MF, Menge T, Hartung HP, Kieseier BC, Frohman EM. (2008) Pharmacological treatment of early multiple sclerosis. Drugs (Jan), 68(1): 73-83.
Zivadinov R, Weinstock-Guttman B, Benedict R, Tamaño-Blanco M, Hussein S, Abdelrahman N, Durfee J, Ramanathan M. (2007) Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet (Nov), 16(22): 2659-2668.
Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stüve O. (2007) Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics (Oct), 4(4): 618-626.
Shah A, Eggenberger E, Zivadinov R, Stüve O, Frohman EM. (2007) Corticosteroids for multiple sclerosis: II. Application for disease-modifying effects. Neurotherapeutics (Oct), 4(4): 627-632.
Weinstock-Guttman B, Zivadinov R, Tamaño-Blanco M, Abdelrahman N, Badgett D, Durfee J, Hussein S, Feichter J, Patrick K, Benedict R, Ramanathan M. (2007) Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol (Aug), 188(1-2): 167-174.
Tekok-Kilic A, Benedict RH, Weinstock-Guttman B, Dwyer MG, Carone D, Srinivasaraghavan B, Yella V, Abdelrahman N, Munschauer F, Bakshi R, Zivadinov R. (2007) Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage (Jul), 36(4): 1294-1300.
Benedict RH, Bruce J, Dwyer MG, Weinstock-Guttman B, Tjoa C, Tavazzi E, Munschauer FE, Zivadinov R. (2007) Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler (Jul), 13(6): 722-730.
Garg N, Zivadinov R, Ramanathan M, Vasiliu I, Locke J, Watts K, Lema J, Rajeswary J, Munschauer FE, Ambrus J, Weinstock-Guttman B. (2007) Clinical and MRI correlates of autoreactive antibodies in multiple sclerosis patients. J Neuroimmunol (Jul), 187(1-2): 159-165.
Tavazzi E, Dwyer MG, Weinstock-Guttman B, Lema J, Bastianello S, Bergamaschi R, Cosi V, Benedict RH, Munschauer FE, Zivadinov R. (2007) Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage (Jul), 36(3): 746-754.
Benedict RH, Zivadinov R. (2007) Reliability and validity of neuropsychological screening and assessment strategies in MS. J Neurol (May), 254 S: 22-25.
Zivadinov R. (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?. Neurology (May), 68(22 Su): 72-82.
Zivadinov R, Locatelli L, Cookfair D, Srinivasaraghavan B, Bertolotto A, Ukmar M, Bratina A, Maggiore C, Bosco A, Grop A, Catalan M, Zorzon M. (2007) Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult Scler (May), 13(4): 490-501.
Parmenter BA, Zivadinov R, Kerenyi L, Gavett R, Weinstock-Guttman B, Dwyer MG, Garg N, Munschauer F, Benedict RH. (2007) Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol (Feb), 29(2): 215-223.
Hoque R, Ledbetter C, Gonzalez-Toledo E, Misra V, Menon U, Kenner M, Rabinstein AA, Kelley RE, Zivadinov R, Minagar A. (2007) The role of quantitative neuroimaging indices in the differentiation of ischemia from demyelination: an analytical study with case presentation. Int Rev Neurobiol (Jan), 79: 491-519.
Weinstock-Guttman B, Tamaño-Blanco M, Bhasi K, Zivadinov R, Ramanathan M. (2007) Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients. J Neuroimmunol (Jan), 182(1-2): 236-239.
Zivadinov R, Uxa L, Bratina A, Bosco A, Srinivasaraghavan B, Minagar A, Ukmar M, Benedetto S, Zorzon M. (2007) HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol (Jan), 79: 521-535.
Zivadinov R, Cox JL. (2007) Neuroimaging in multiple sclerosis. Int Rev Neurobiol (Jan), 79: 449-474.
Dolezal O, Dwyer MG, Horakova D, Havrdova E, Minagar A, Balachandran S, Bergsland N, Seidl Z, Vaneckova M, Fritz D, Krasensky J, Zivadinov R. (2007) Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol (Jan), 79: 475-489.
Chadha K, Weinstock-Guttman B, Zivadinov R, Bhasi K, Muhitch J, Feichter J, Tamaño-Blanco M, Abdelrahman N, Ambrus J, Munschauer F, Ramanathan M. (2006) Interferon inhibitory activity in patients with multiple sclerosis. Arch Neurol (Nov), 63(11): 1579-1584.
Sharma J, Zivadinov R, Jaisani Z, Fabiano AJ, Singh B, Horsfield MA, Bakshi R. (2006) A magnetization transfer MRI study of deep gray matter involvement in multiple sclerosis. J Neuroimaging (Oct), 16(4): 302-310.
Frohman E, Costello F, Zivadinov R, Stuve O, Conger A, Winslow H, Trip A, Frohman T, Balcer L. (2006) Optical coherence tomography in multiple sclerosis. Lancet Neurol (Oct), 5(10): 853-863.
Benedict RH, Bruce JM, Dwyer MG, Abdelrahman N, Hussein S, Weinstock-Guttman B, Garg N, Munschauer F, Zivadinov R. (2006) Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (Sep), 63(9): 1301-1306.
Santos R, Weinstock-Guttman B, Tamaño-Blanco M, Badgett D, Zivadinov R, Justinger T, Munschauer F, Ramanathan M. (2006) Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies. J Neuroimmunol (Jul), 176(1-2): 125-133.
Benedict RH, Zivadinov R. (2006) Predicting neuropsychological abnormalities in multiple sclerosis. J Neurol Sci (Jun), 245(1-2): 67-72.
Carone DA, Benedict RH, Zivadinov R, Singh B, Ambrus JL. (2006) Progressive cerebral disease in lymphomatoid granulomatosis causes anterograde amnesia and neuropsychiatric disorder. J Neuroimaging (Apr), 16(2): 163-166.
Fritz DA, Dwyer MG, Bagnato F, Watts KL, Bratina A, Zorzon M, Durastanti V, Locatelli L, Millefiorini E, Zivadinov R. (2006) Effect of MRI coregistration on serial short-term brain volume changes in multiple sclerosis. Neurol Res (Apr), 28(3): 275-279.
Tekok-Kilic A, Benedict RH, Zivadinov R. (2006) Update on the relationships between neuropsychological dysfunction and structural MRI in multiple sclerosis. Expert Rev Neurother (Mar), 6(3): 323-331.
Carone DA, Benedict RH, Dwyer MG, Cookfair DL, Srinivasaraghavan B, Tjoa CW, Zivadinov R. (2006) Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS. Neuroimage (Jan), 29(2): 505-514.
Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. (2005) Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol (Oct), 62(10): 1519-1530.
Benedict RH, Zivadinov R, Carone DA, Weinstock-Guttman B, Gaines J, Maggiore C, Sharma J, Tomassi MA, Bakshi R. (2005) Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol (Aug), 26(7): 1824-1831.
Zorzon M, Zivadinov R, Locatelli L, Giuntini D, Toncic M, Bosco A, Nasuelli D, Bratina A, Tommasi MA, Rudick RA, Cazzato G. (2005) Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol (Jul), 12(7): 550-556.
Zivadinov R. (2005) Steroids and brain atrophy in multiple sclerosis. J Neurol Sci (Jun), 233(1-2): 73-81.
Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, Weinstock-Guttman B. (2005) Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (Apr), 231(1-2): 29-34.
Zivadinov R, Grop A, Sharma J, Bratina A, Tjoa CW, Dwyer M, Zorzon M. (2005) Reproducibility and accuracy of quantitative magnetic resonance imaging techniques of whole-brain atrophy measurement in multiple sclerosis. J Neuroimaging (Jan), 15(1): 27-36.
Zivadinov R, Leist TP. (2005) Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging (Jan), 15(4 Sup): 10-21.
Locatelli L, Zivadinov R, Grop A, Zorzon M. (2004) Frontal parenchymal atrophy measures in multiple sclerosis. Mult Scler (Oct), 10(5): 562-568.
Sanfilipo MP, Benedict RH, Zivadinov R, Bakshi R. (2004) Correction for intracranial volume in analysis of whole brain atrophy in multiple sclerosis: the proportion vs. residual method. Neuroimage (Aug), 22(4): 1732-1743.
Zivadinov R, Bagnato F, Nasuelli D, Bastianello S, Bratina A, Locatelli L, Watts K, Finamore L, Grop A, Dwyer M, Catalan M, Clemenzi A, Millefiorini E, Bakshi R, Zorzon M. (2004) Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci (Aug), 223(2): 185-193.
Zivadinov R, Bakshi R. (2004) Central nervous system atrophy and clinical status in multiple sclerosis. J Neuroimaging (Jul), 14(3 Sup): 27-35.
Bagnato F, Zivadinov R, Cecchinelli D, Tancredi A, Grop A, Pierallini A, De Lena C, Prencipe M, Reale G, Zorzon M, Millefiorini E. (2004) beta2-microglobulin serum level is not a marker of disease activity in multiple sclerosis. Eur J Neurol (Jul), 11(7): 455-460.
Fiotti N, Zivadinov R, Altamura N, Nasuelli D, Bratina A, Tommasi MA, Bosco A, Locatelli L, Grop A, Cazzato G, Guarnieri G, Giansante C, Zorzon M. (2004) MMP-9 microsatellite polymorphism and multiple sclerosis. J Neuroimmunol (Jul), 152(1-2): 147-153.
Zivadinov R, Bakshi R. (2004) Role of MRI in multiple sclerosis I: inflammation and lesions. Front Biosci (Jan), 9: 665-683.
Zivadinov R, Bakshi R. (2004) Role of MRI in multiple sclerosis II: brain and spinal cord atrophy. Front Biosci (Jan), 9: 647-664.
Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti-Bragadin L, Cazzato G. (2003) A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci (Dec), 216(1): 113-118.
Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, Tommasi MA, Locatelli L, Cazzato G. (2003) Risk factors of multiple sclerosis: a case-control study. Neurol Sci (Nov), 24(4): 242-247.
Zivadinov R, Locatelli L, Stival B, Bratina A, Grop A, Nasuelli D, Brnabic-Razmilic O, Zorzon M. (2003) Normalized regional brain atrophy measurements in multiple sclerosis. Neuroradiology (Nov), 45(11): 793-798.
Fabiano AJ, Sharma J, Weinstock-Guttman B, Munschauer FE, Benedict RH, Zivadinov R, Bakshi R. (2003) Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (Oct), 13(4): 307-314.
Zivadinov R, Uxa L, Zacchi T, Nasuelli D, Ukmar M, Furlan C, Pozzi-Mucelli R, Tommasi MA, Locatelli L, Ulivi S, Bratina A, Bosco A, Grop A, Cazzato G, Zorzon M. (2003) HLA genotypes and disease severity assessed by magnetic resonance imaging findings in patients with multiple sclerosis. J Neurol (Sep), 250(9): 1099-1106.
Zivadinov R, Willheim K, Sepic-Grahovac D, Jurjevic A, Bucuk M, Brnabic-Razmilic O, Relja G, Zorzon M. (2003) Migraine and tension-type headache in Croatia: a population-based survey of precipitating factors. Cephalalgia (Jun), 23(5): 336-343.
Zivadinov R, Zorzon M, Locatelli L, Stival B, Monti F, Nasuelli D, Tommasi MA, Bratina A, Cazzato G. (2003) Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. J Neurol Sci (Jun), 210(1-2): 73-76.
Zorzon M, Zivadinov R, Locatelli L, Stival B, Nasuelli D, Bratina A, Bosco A, Tommasi MA, Pozzi Mucelli RS, Ukmar M, Cazzato G. (2003) Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. Mult Scler (Feb), 9(1): 108-110.
Zivadinov R, Iona L, Monti-Bragadin L, Bosco A, Jurjevic A, Taus C, Cazzato G, Zorzon M. (2003) The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology (Jan), 22(1): 65-74.
Zivadinov R, Zorzon M. (2002) Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature. J Neuroimaging (Oct), 12(4): 302-309.
Zorzon M, Zivadinov R, Nasuelli D, Ukmar M, Bratina A, Tommasi MA, Mucelli RP, Brnabic-Razmilic O, Grop A, Bonfigli L, Cazzato G. (2002) Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol (Sep), 9(5): 491-496.
Zorzon M, Capus L, Pellegrino A, Cazzato G, Zivadinov R. (2002) Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy. Acta Neurol Scand (Feb), 105(2): 77-82.
Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology (Oct), 57(7): 1239-1247.
Zivadinov R, Willheim K, Jurjevic A, Sepic-Grahovac D, Bucuk M, Zorzon M. (2001) Prevalence of migraine in Croatia: a population-based survey. Headache (Sep), 41(8): 805-812.
Zorzon M, Zivadinov R, Monti Bragadin L, Moretti R, De Masi R, Nasuelli D, Cazzato G. (2001) Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. J Neurol Sci (Jun), 187(1-2): 1-5.
Zivadinov R, Sepcic J, Nasuelli D, De Masi R, Bragadin LM, Tommasi MA, Zambito-Marsala S, Moretti R, Bratina A, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. (2001) A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (Jun), 70(6): 773-780.
Moretti R, Bava A, Torre P, Antonello RM, Zorzon M, Zivadinov R, Cazzato G. (2001) Bilingual aphasia and subcortical-cortical lesions. Percept Mot Skills (Jun), 92(3 Pt): 803-814.
Zorzon M, de Masi R, Nasuelli D, Ukmar M, Mucelli RP, Cazzato G, Bratina A, Zivadinov R. (2001) Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol (May), 248(5): 416-421.
Zivadinov R, De Masi R, Nasuelli D, Bragadin LM, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M. (2001) MRI techniques and cognitive impairment in the early phase of relapsing-remitting multiple sclerosis. Neuroradiology (Apr), 43(4): 272-278.
Zorzon M, Ukmar M, Bragadin LM, Zanier F, Antonello RM, Cazzato G, Zivadinov R. (2000) Olfactory dysfunction and extent of white matter abnormalities in multiple sclerosis: a clinical and MR study. Mult Scler (Dec), 6(6): 386-390.
Zivadinov R, Zorzon M, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Iona LG, Cazzato G. (1999) Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler (Dec), 5(6): 428-431.
Zorzon M, Zivadinov R, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Morassi P, Iona LG, Cazzato G. (1999) Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler (Dec), 5(6): 418-427.
Zivadinov R, Zorzon M, Monti Bragadin L, Pagliaro G, Cazzato G. (1999) Olfactory loss in multiple sclerosis. J Neurol Sci (Oct), 168(2): 127-130.
Cazzato G, Antonello RM, Zorzon M, Torre P, Zivadinov R, Moretti R, Bragadin LM, De Masi R, Nasuelli D. (1999) [Treatment of multiple sclerosis. The present and the future. Study Group on Diagnosis and Therapy of Multiple Sclerosis]. Recenti Prog Med (Oct), 90(10): 538-544.
Zivadinov R, Jurjevic A, Willheim K, Cazzato G, Zorzon M. (1998) Incidence and prevalence of myasthenia gravis in the county of the coast and Gorski kotar, Croatia, 1976 through 1996. Neuroepidemiology (Jan), 17(5): 265-272.

See all (431 more)

Abstracts:

Goldberg H, Weinstock A, Dwyer M, Bergsland N, Sazgar M, Poloni G, Zivadinov R. (2011) Automated Segmentation of Brain MRI for Quantification of Cortical and Subcortical Atrophy in Patients with Temporal Lobe Epilepsy. (Apr)
Zhang L, Dwyer M, Kerr S, Finnegan S, Zivanidov R, Weinstock A. (2004) Source Analysis of Interictal Sharp Waves in Focal Epilepsy. (Dec)

Professional Memberships:

American Neurological Association (2015–present)
European Academy of Neurology (2014–present)
International Society for Neurovascular Diseases (2011–present)
International Society for Magnetic Resonance Imaging (2005–present)
Italian Neurological Society (2004–present)
European Neurological Society (2004–present)
American Academy of Neurology (2003–present)
American Society of Neuroimaging (2003–present)
Croatian Society of Neurology (2001–present)
Italian Neurological Society of Triveneto (1997–present)

Presentations:

"Thalamic injury and cognition/fatigue in multiple sclerosis" 17th annual ARSEP (French MS society) MRI workshop - Thalamus & Multiple Sclerosis (CME) (2022)
"Detecting demyelination and remyelination by MRI in the CNS (CME; Course Director)" Consortium of Multiple Sclerosis Centers-Recovery and Repair: Remyelination and Clinical Trials (2021)
"Imaging biomarkers of disease progression in multiple sclerosis (CME)" 4th Rijeka Forum on neurodegenerative diseases-neurodegenerative diseases and COVID 19 Pandemic. (2020)
"Brain imaging research and neurological disease" Boldly Buffalo, The Campaign for UB (2018)
"Advances in imaging of multiple sclerosis" 3rd Annual Meeting, of Russian Committee for Treatment and Research in Multiple Sclerosis (RUCTRIMS) (2018)
"Role of cardiovascular comorbidities in the pathogenesis of neurological disorders" 8th Annual International Society of Neurovascular Disorders (ISNVD) (2018)
"Is the central vein syndrome really helpful in differentiating MS from other white-matter disease – PRO (CME)" 12th World Congress of Controversies in Neurology (CONy) (2018)
"Progressive forms of MS respond to agents used for relapsing forms of the disease – CONS (CME)" 12th World Congress of Controversies in Neurology (CONy), (2018)
"Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
"Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
"Brain atrophy and predicting physical and cognitive disability in MS: Clinical relevance, the body of evidence and practical considerations (CME)" Sanofi-Genzyme Medical Meeting (2018)
"Watching the hourglass: disease monitoring and detecting disease activity in MS (CME)" Sanofi-Genzyme Medical Meeting (2018)
"A case-control, 5 year follow study of cardiovascular, environmental and genetic risk factors for disease progression in patients with MC (CEG-MS study) (CME)" 7th Annual International Society for Neurovascular Disorders (ISNVD) Meeting (2017)
"Effect of a cerebral protection device on brain lesions following TAVI in patients with severe aortic stenosis (CME)" 7th Annual International Society for Neurovascular Disorders (ISNVD) Meeting (2017)
"Brain atrophy should be used to guide therapy in multiple sclerosis: PRO (CME)" 11th World Congress of Controversies in Neurology (CONy) (2017)
"Leptomeningeal enhancement on MRI is a promising biomarker to monitor disease worsening, especially in progressive MS: PRO (CME)" 11th World Congress of Controversies in Neurology (CONy) (2017)
"Evaluation of Aubagio MRI efficiency" Academy of Knowledge, Scientific Exchange Forum (2017)
"Lemtrada outcome measures in the context of evolving treatment goals in MS" Academy of Knowledge, Scientific Exchange Forum (2017)
"Clinical relevance of brain atrophy in multiple sclerosis" 2nd MS Genzyme Summit (2017)
"Prognostic indicators of multiple sclerosis: Predicting disability" 2nd MS Genzyme Summit (2017)
"Evaluation of Aubagio MRI efficacy" Academy of Knowledge, Scientific Exchange Forum (2016)
"Preserving brain volume in multiple sclerosis." 14th PanAmerican Congress (2016)
"Susceptibility-weighted imaging and quantitative susceptibility mapping in the clinical trials of multiple sclerosis." 4th Workshop on MRI phase contrast & quantitative susceptibility mapping (QSM) (2016)
"A case-control, 5-year follow-up study of cardiovascular, environmental and genetic risk factors for disease progression in patients with MS (CEG-MS study)." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
"Abnormal posture control of internal jugular vein flow is associated with brain atrophy progression in multiple sclerosis patients over 5 years." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
"Cerebral microbleeds in multiple sclerosis. A case-control Study" 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
"Heart and brain in neurodegeneration: Venous prespective." 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease (2016)
"Leptomeningeal contrast enhancement is associated with development of gray matter atrophy over 5 years in multiple sclerosis." 68th Annual Meeting of American Academy of Neurology; American Academy of Neurology (2016)
"Neurological Software Tool for Reliable Atrophy Measurement (NeuroSTREAM) in Multiple Sclerosis." 68th Annual Meeting of American Academy of Neurology; American Academy of Neurology (2016)
"Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis; The GALA study MRI and 36 month update" 8th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS) Congress; PACTRIMS Congress (2015)
"No evidence of disease activity in treated patients after first clinical event suggestive of multiple sclerosis - follow-up study." Congress of the European Committee for Treatment and Research in Multiple Sclerosis,; ECTRIMS (2015)
"Cardiovascular risk factors and neurodegenerative disorders" 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
"Internal jugular vein cross-sectional area and cerebrospinal fluid pulsatility in the aqueduct of Sylvius" 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
"Prevalence of chronic cerebrospinal venous insufficiency in multiple sclerosis. Results of large cohort case-control ctudy." 5th Annual Meeting of International Society for Neurovascular Disease; International Society for Neurovascular Disease (2015)
"Biomarkers of neurodegeneration in multiple sclerosis." 7th Pan-Asian Committee for Treatment and Research in Multiple Sclerosis; PACTRIMS Congress (2014)
"CLEAN-TAVI: A prospective, randomized trial of cerebral embolic protection in high-risk patients with aortic stenosis undergoing transcatheter aortic valve replacement." TCT Late Breaking News; TCT Late Breaking News (2014)
"Implications of DW-MRI and FLAIR signals from clinical Studies" TCT Claret Medical Satellite Symposium; Claret Medical (2014)
"Effect of terifllunomide (Aubagio) on gray matter pathology in Multiple Sclerosis: The 12 month, prospective, observational, single-blinded, longitudinal study" 2nd Genzyme Global Medical Summit; Genzyme (2014)
"Monotherapy of INT131 or placebo in the treatment of RRMS: Phase II trial design MRI specific study procedures" Protocol INT131-RU01-02 Investigator Meeting; Protocol INT131-RU01-02 Investigator Meeting (2014)
"Can we judge the efficacy of disease-modifying medications based on their effects on MRI brain atrophy?" The 8th World Congress on Controversies in Neurology; CONy (2014)
"Regeneration and remyleination are possible in MS lesions." The 8th World Congress on Controversies in Neurology; CONy (2014)
"CCSVI is associated with subcortical deep gray matter abnormalities in healthy individuals; A diffusion tensor MRI study." 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
"Identifying CCSVI with cervical plethysmography; TELEPASS study and Kosmomed project presentation." 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
"Inverse relationship between internal jugular vein narrowing and increased brain volumes in health individuals" 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
"Why we need a multi-modality diagnostic approach for CCSVI" 4th Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease (2014)
"Development of grey matter atrophy in relapsing remitting MS is not gender-dependent: results of a five-year follow-up study." 29th European Committee for Treatment and Research in MS; ECTRIMS; Multiple Sclerosis (2013)
"The role of noninvasive and invasive diagnostic imaging techniques for the detection of extracranial venous system anomalies and development variants (CME)" 2013 Annual Meeting of the Taiwan Stroke Society; Taiwan Stroke Society; Neurology (2013)
"Venous involvement in neurological disorders and aging (CME)" 2013 Annual Meeting of the Taiwan Stroke Society; Taiwan Stroke Society; Neurology (2013)
"The value of phase and susceptibility imaging in the study of multiple sclerosis, neurological diseases and aging." 2nd Workshop on MRI phase contrast & quantitative susceptibility mapping (QSM); Cornell University; Neuroradiology (2013)
"Assessing and managing neuropsychiatric problems in MS: From MRI to treatment (CME)" Consortium of MS Centers, Chicago, IL; Consortium of MS Centers; Neuropsychiatric - MRI (2013)
"A multinational, multicenter, randomized, placebo-controlled, double-blinded study to assess the efficacy, safety and tolerability of glatiramer acetate 40 mg injection three times per week in subjects with RRMS: efficacy and safety results of GALA study" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
"Cortical, thalamic- and subcortical grey matter atrophy as predictors of cognitive dysfunction in patients with multiple sclerosis: A 10-year follow-up study." 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
"Gray matter pathology in multiple sclerosis: modern views on the role of thalamus and cortical atrophy (CME)." Michigan State University Resident Lecture; Michigan State University; MS (2013)
"Multimodal imaging manifestations of neuropsychiatric involvement in systemic lupus" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuropsychiatry (2013)
"Thalamic atrophy is associated with the development of clinically definite MS" 65th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2013)
"Thalamus moves in MS spotlight (CME; GR)" SUNY Buffalo Department of Neurology - Grand Rounds Lecture; State University of New York at Buffalo; Multiple Sclerosis (2013)
"Changes of cine cerebrospinal fluid dynamics in multiple sclerosis patients treated with venous angioplasty" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
"Chronic cerebrospinal venous insufficiency (CCSVI) in pediatric multiple sclerosis and other neurologic disorders." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
"Chronic cerebrospinal venous insufficiency at ECTRIMS 2012." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Venous Insufficiency (2013)
"Comparison of intravascular ultrasound (IVUS) to gold standard ctheter venography (CV) for the detection of extra-cranial venous abnormalities indicative of CCSVI: Results of the PREMiSe study" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
"Multimodal diagnostic comparisons of 2 invasive and 2 non-invasive techniques in the Prospective Randomized Endovascular Treatment of MS PREMiSe study" 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2013)
"The impact of chronic cerebrospinal venous insufficiency on intracranial physiology in healthy individuals." 3rd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Chronic Venous Insufficiency (2013)
"A Phase 3 trial to assess the efficacy and safety of glatiramer acetate injections 40 mg administered 3 times a week compared to placebo." 28th European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2012)
"Relative contribution of thalamus volume and diffusion tensor metrics to cognitive impairment in multiple sclerosis." 28th European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2012)
"Cine cerebrospinal fluid imaging in multiple sclerosis and after endovascular treatment for CCSVI" 4th European Annual Meeting for minimal Invasive Surgery.; European Annual Meeting for minimal Invasive Surgery; Multiple Sclerosis (2012)
"Iron deposition in the subcortical deep-gray matter of pediatric multiple sclerosis patients" 64th American Academy of Neurology Annual Meeting; American Academy of Neurology; Multiple Sclerosis (2012)
"Subcortical deep gray matter SWI-filtered phase and atrophy are associated with disability in MS." 64th American Academy of Neurology Annual Meeting; American Academy of Neurology; Multiple Sclerosis (2012)
"Iron deposition and disability in Multiple Sclerosis" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
"Iron deposition in clinically isolated syndrome" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
"Is CCSVI a disease?" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
"Morphological MRV multimodal studies in CCSVI" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
"MRI outcomes in multiple sclerosis" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
"Perfusion changes in CCSVI" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
"Venous and CSF flow in brain parenchyma of MS patients" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Multiple Sclerosis (2012)
"Venous involvement in neurological disorders" 2nd Annual ISNVD Scientific Meeting; International Society for Neurovascular Disease; Neurology (2012)
"Susceptibility-weighted imaging in neurological disorders" 35th Annual Meeting of the American Society of Neuroimaging; American Society of Neuroimaging; Neuroimaging (2012)
"Hypoperfusion of brain parenchyma in CCSVI" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Neurology (2011)
"Intraluminal and extraluminal extra-cranial structural and functional venous abnormalities multiple sclerosis patients and healthy controls." 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Multiple Sclerosis (2011)
"Iron and veins in Multiple Sclerosis" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Multiple Sclerosis (2011)
"The limits of magnetic resonance venography for the diagnosis of chronic cerebrospinal venous insufficiency" 1st Congress of the International Society for Neurovascular Disease; International Society for Neurovascular Disease; Neurology (2011)
"Hot topics in MS: Disease fundamentals and management of benefits and risks" The 5th Teva MS Experts Board Meeting (2010)
"Chronic cerebrospinal venous insufficiency: Relation to multiple sclerosis." 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2010)
"Presence and severity of Chronic Cerebrospinal Venous Insufficiency is related to lower brain parenchyma venous vasculature visibility on susceptibility-weighted imaging in patients with Multiple Sclerosis" 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2010)
"Chronic cerebrospinal venous insufficiency in Multiple Sclerosis" 62nd Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
"Independent associtions of basal ganglia, thalamus and neocortical atrophy with slowed cognitive processing in multiple sclerosis" 63rd Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
"MRI measures in GALA study" GALA study (2010)
"Neurodegeneration and CNS repair in MS: MRI evidence (CME)" Advanced imaging techniques in MS (2010)
"Qualitative brain MRI features in children diagnosed with multiple sclerosis" 63rd Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2010)
"Susceptibility-weighted imaging in neurological disorders" 62nd Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuroimaging (2010)
"Advanced imaging and chronic cerebrospinal venous insufficiency outcomes in multiple sclerosis" (2010)
"Advanced imaging in MS (CME)" Neurologic-Rhematologic Symposium (2010)
"Chronic cerebrospinal venous insufficiency and MRI outcomes in multiple sclerosis" CCSVI in MS (2010)
"Endovascular treatment for chronic cerebrospinal venous insufficiency in multiple sclerosis; A longitudinal pilot study." 22nd Annual Meeting of American Venous Forum; The American Venous Forum; Multiple Sclerosis (2010)
"Chronic cerebrospinal venous insufficiency in multiple sclerosis" Intiture College of Neurology (2009)
"DMTs and MRI markers of neurodegeneration and CNS repair" Advanced imaging in MS (2009)
"Evidence for remyelination in Multiple Sclerosis" 23rd Slovakian Neurological Congress; Slovakian Neurological Congress; Multiple Sclerosis (2009)
"Neuroimaging of MS: State of the art and future directions." The Neuroradiology Education and Research Foundation; American Society of Neuroradiology; Neuroradiology (2009)
"Dirty appearing white matter on 1.5 and 3 tesla brain MRI in multiple sclerosis" 30th Congress of the Italian Neurological Society; Congress of The Italian Neurological Society; Multiple Sclerosis (2009)
"Advanced Imaging Techniques in Multiple Sclerosis: A Gaze into the Future" (2009)
"The Role of Gray Matter Damage in MS (CME)" Multiple Sclerosis & Parkinson Disease: Recent Developments & New Perspectives (2009)
"Advances in magnetic resonance imaging of multiple sclerosis (CME)" Annual Meeting of American Academy of Neurology, (2009)
"Advances in MS Neuroimaging (CME)" 12th Annual Review of Multiple Sclerosis & Parkinson's Disease, (2009)
"The role of gray matter pathology in MS (CME)" MRI and MS: From scientific to clinical routine evidence (2009)
"Multiple Sclerosis scientific topic highlights" 61st Annual Meeting of The American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2009)
"Sensitive and noise-resistant identification of voxel-wise changes in magnetization transfer ratio via cluster enhancement and M-estimator-based Monte Carlo simulation" 17th Annual ISMRM Meeting; ISMRM; Neuroimaging (2009)
"The role of gray matter pathology in MS (CME)" (2009)
"Gray matters: Impact of disease-modifying therapies and gray matter on the brain in MS patients (CME)" (2009)
"Practical Issues in Multiple Sclerosis: Imaging Concepts in MS (CME)" University of South Florida, Practical Issues in MS, Visiting Professors Series (2009)
"Neuroprotective effect of IM Inteferon-beta- 1a in MS: New evidences on brain atrophy." 29th Congress of Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2008)
"Immunomodulation and neuroprotection: MRI perspectives." 24th Joint Annual Meeting of ECTRIMS, ACTRIMS and LACTRIMS; ECTRIMS, ACTRIMS and LACTRIMS; Neuroradiology (2008)
"New MRI advances in MS (CME; GR)" ; ; University of Missisipi, Department of Neurology, (2008)
"Using brain imaging to measure potential remyelination processes" The 2nd Teva Myelin Repair Meeting (2008)
"Long term effect of disease modifying therapies â€“ New emerging MRI techniques in monitoring abnormalities and disability in MS" 5th LATAM (Latin America Multiple Sclerosi Meeting), (2008)
"Neuroprotection in MS as evidenced by MRI (CME; GR)" (2008)
"Using brain imaging to measure potential remyelination processes (CME; GR)" (2008)
"Can we measure remyelination with MRI in MS ? (CME; GR)" (2008)
"Advanced Imaging Techniques: New Management Strategies for Multiple Sclerosis and Parkinsonâ€™s Disease (CME)" (2008)
"Advanced MRI techniques in MS (CME; GR)" (2008)
"Demyelination and remyelination as evidenced by MRI in MS (CME; GR)" (2008)
"Update on MRI in MS (CME)" (2008)
"Is MRI a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis?" European Charcot Foundation Symposium, 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, (2007)
"Role of MRI in imaging of myelin" 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, (2007)
"Extent of deep gray matter atrophy in patients with multiple sclerosis; A case control study." 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
"Hippocampal volume does not correlate with memory impairment in Multiple Sclerosis" 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
"Is MRI a reliable tool for the prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? A 5-year longitudinal study." 17th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2007)
"Retinal nerve fiber layer thickness is associated with brain MRI outcome in multiple sclerosis patients." 21st Annual Meeting of the Consortium of Multiple Sclerosis Patients; Consortium of MS Centers; Multiple Sclerosis (2007)
"Severity of spinal cord atrophy is moderately related to severity of brain MRI measures in patients with MS" 17th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2007)
"Thle place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcomes (CME)" The 6th Teva and Sanofi-Aventis International Symposium on MS, Translating new insights on disease progression into treatment optimization in MS, (2007)
"Evidence for remyelination and regeneration by using MRI techniques in MS (CME; GR)" (2007)
"MRI and differential diagnosis of MS (CME)" (2007)
"Neuroprotection in Multiple Sclerosis: Can We Measure Neuroprotection & Remyelination With Imaging Techniques (CME; GR)" ; ; Department of Neurology, University of Hamilton (2007)
"Role of MRI in MS (CME)" ; ; Department of Neurology, University of Hamilton, (2007)
"Remyelination and neuroprotection as evidenced by MRI (CME)" (2007)
"Evidence for Neuroprotection in Multiple Sclerosis: Can We Measure Neuroprotection & Remyelination With Imaging Techniques (CME; GR)" (2007)
"Inflammation and Neurodegeneration in MS as Evidenced by MRI: Current Knowledge and Future Perspectives (CME)" (2006)
"Application of MRI in making diagnosis and prognosis of MS (CME; GR)" (2006)
"Efficacy results from a randomized, double-blinded, placebo-controlled study of intramuscular interferon beta - 1a, azatheoprince and corticosteroid combination therapy in patients with relapsing-remitting multiple sclerosis." 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; ECTRIMS; Multiple Sclerosis (2006)
"MRI evidence for neuroprotection and remyelination (CME; GR)" (2006)
"Understanding of MS through MRI (CME)" (2006)
"MRI in pediatric MS" National Multiple Sclerosis Society meeting; (2006)
"Improving adherence and treatments outcomes in MS: A multifaceted challenge" Annual Meeting of the Consortium of Multiple Sclerosis Centers; ; Biogen Idec Inc. (2006)
"Inflammation and neurodegeneration in MS as Evidenced by MRI: Implications for current and future therapies" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Teva Neuroscience Inc. (2006)
"MS management: Using history to guide the future" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Teva Neuroscience Inc. (2006)
"The natural history of benign multiple sclerosis" Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of MS Centers; Multiple Sclerosis (2006)
"Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis." 16th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2006)
"Impact of spatial distribution of T2 and T1 lesion volume on processing speed in patients with multiple sclerosis" 16th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2006)
"Inflammation and neurodegeneration in MS: Evidence from MRI studies (CME: GR)" (2006)
"T1 intensity differences to normal appearing white matter in hypointense lesions on MRI are related to clinical status in multiple sclerosis." 16th meeting of the European Neurological Society; European Neurological Society; Neuroimaging (2006)
"Aging with MS and other neurodegenerative diseases (CME; GR)" (2006)
"Evolution of Benign Multiple Sclerosis in the New York State Multiple Sclerosis Consortium According to Different Classification Criteria" 58th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2006)
"Interferon Inhibitory Activities in Multiple Sclerosis Patients" 58th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2006)
"MRI in MS: Neurodegeneration and neuroprotection (CME; GR)" (2006)
"Multiple Sclerosis: Imuunological, genetic and clinical characteristics (CME; GR)" (2006)
"CNS atrophy in MS" Regional MS meeting: New frontiers in imaging (2006)
"MRI in MS: New MRI and immunological concepts (CME)" (2006)
"Pathogenesis of MS and MRI correlations" (2006)
"Rationale for diagnostic MRI criteria and new imaging techniques" Regional MS meeting: New frontiers in imaging, (2006)
"Role of emerging MRI techniques in MS (CME: GR)" (2006)
"Role of MRI in diagnosis and prognosis of MS: Rationale for early treatment" Regional MS Forum Middle East (2006)
"Inflammation and neurodegeneration as edvidenced by use of MRI (CME)" ; ; University of South Florida, Practical Issues in MS, Visiting Professors Series (2006)
"Corticosteroids in MS" NMSS Task Force meeting on role of steroids in MS (2005)
"MRI in MS: New concepts (CME)" (2005)
"Application of MRI in MS: What we learned in the last decade" National Multiple Sclerosis Society Annual Meeting (2005)
"Corticosteroid therapy in multiple sclerosis" University Classes in Multiple Sclerosis, European Charcot Foundation, (2005)
"Inflammation and neurodegeneration in MS: What lessons we learned in the last decade using MRI (JMC)" (2005)
"Controversis in neuropsychology of multiple sclerosis: Role of structural MRI in detecting cognitive impairment in patients with Multiple Sclerosis" Serono Symposia International (2005)
"Magnetic Resonance Imaging in MS: What we learned in the last decade (CME)" (2005)
"MRI as marker of neurodegeneration in MS (CME; GR)" (2005)
"Neuroimaging in multiple sclerosis: Nonconventinal MRI measure in MS (CME)" (2005)
"The meaning and application of MRI in MS (CME)" (2005)
"Utilizing MRI to diagnose and treat multiple sclerosis (CME; GR)" (2005)
"Evaluation of effect of disease-modifying treatment on conventional and nonconventional MRI measures (CME; GR)" (2005)
"Neurodegeneration and neuroprotection evaluated by different non-conventional MRI measures (JMC)" (2005)
"Pseudoatrophy and irreversible atrophy in MS" (2005)
"Quantitative analysis of lesion load progression in advanced multiple sclerosis" 21st Congress of the European Committee for the Treatment and Research in MS; ECTRIMS; Multiple Sclerosis (2005)
"Update on MRI in MS: New evidence for neurodegeneration" (2005)
"Use of MRI in multiple sclerosis" National Multiple Sclerosis Society (2005)
"Overview of Buffalo Neuroimaging Analysis Center MRI activities" (2005)
"Relation of cognitive dysfunction to multiple neuroimaging measures in multiple sclerosis over time" 57th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Neuroimaging (2005)
"New advances in managing MS - Magnetic resonance imaging in MS: Neurodegeneration and neuroprotection (CME)" (2005)
"Buffalo Neuroimaging Analysis Center database approach experience. A new model for magnetic resonance imaging and clinical and research studies (CME)" ; University of Cincinnati (2004)
"Magnetic resonance imaging in multiple sclerosis. Beyond enhancement and T2 (CME)" Thomas Jefferson University Neurology Resident CME Conference, (2004)
"Identifying disease modifying genes in multiple sclerosis. Clinical and MRI correlations" ; ; Harvard Medical School (2004)
"Application of MRI in multiple sclerosis and Assessment of treatment effect (CME)" (2004)
"Application of the non-conventional MRI in the sudy of MS" (2004)
"Long-term efficacy outcomes of diseasemodifying therapy in multiple sclerosis" Dompeâ€™ Biotec Symposium 35th Congress of Italian Neurol. Society (2004)
"Steroid therapy and multiple sclerosis" ; ; Harvard Medical School (2004)
"Accuracy of segmentation with different brain atrophy techniques" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of Multiple Sclerosis Centers; Neuroimaging (2004)
"Application of global and regional MRI measures in the study of multiple sclerosis" (2004)
"Dompeâ€™ Biotec Symposium 35th Congress of Italian Neurol. Society" ; ; Dept of Neurology, McGill University; (2004)
"Estimation of cerebral grey and white matter atrophy from various MRI pulse sequences" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of Multiple Sclerosis Centers; Multiple Sclerosis (2004)
"Evolution of confluent T2 lesions in relapsing-remitting multiple sclerosis" 18th Annual Meeting of the Consortium of Multiple Sclerosis Centers; Consortium of MS Centers; Multiple Sclerosis (2004)
"Global and regional MRI measures in the study of multiple sclerosis" ; ; Dept of Neurology, University of British Columbia; (2004)
"Bone mineral density in patients with relapsing-remitting multiple sclerosis treated with iv methylprednisolone pulses" 7th Congress of the European Society for Clinical Neuropharmacology; European Society for Clinical Neuropharmacology; Multiple Sclerosis (2004)
"Quality of life and side effects in patients with relapsing-remitting multiple sclerosis treated with interferon beta 1a" 7th Congress of the European Society for Clinical Neuropharmacology; European Society for Clinical Neuropharmacology; Multiple Sclerosis (2004)
"Regional-lobar or whole brain atrophy and clinical status in multiple sclerosis" 56th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2004)
"The Val66Met Polymorphism of Brain Derived Neurotrophic Factor is Associated with an Earlier Age of Disease Onset and more Destructive Brain MRI Pathology in MS Patients" 56th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2004)
"Application of Quantitative MRI in diagnosis and prognosis of multiple sclerosis (CME; GR)" (2004)
"Application of Quantitative MRI in diagnosis and prognosis of multiple sclerosis- Assessment of treatment effect (CME)" ; ; Department of Clinical Neurological Sciences, University of Western Ontario (2004)
"Effect of intravenous methyl-prednisolone on brain atrophy and confluent T2 lesions in relapsing-remitting multiple sclerosis" 9th European Charcot Foundation, (2003)
"Longitudinal study of MRI" 34th Congress of Italian Neurol. Society (2003)
"The evaluation of disease course by means of MRI" Scientific meeting on Multiple Sclerosis (2003)
"MMP-9 microsatellite polymorphism and multiple sclerosis" 13th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2003)
"Ring-Enhancement Pattern May Contribute to More Severe Disability Progression and Higher Disease Activity in the Short Term in Relapsing-Remitting MS" 55th Annual Meeting of the American Academy of Neurology; American Academy of Neurology; Multiple Sclerosis (2003)
"Brain and spinal cord atrophy in multiple sclerosis" 26th Annual Meeting, American Society of Neuroimaging, New Orleans, (2003)
"A comparison of different quantitative MRI techniques to measure whole brain atrophy in relapsing-remitting multiple sclerosis" 32nd Congress of the Italian Neurological Society; Italian Neurological Society; Neuroimaging (2002)
"MMP-9 microsatellite polymorphism increases the risk of multiple sclerosis." 18th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis; Americas Committee for the Treatment and Research in MS; Multiple Sclerosis (2002)
"Short-term brain atrophy changes in relapsing-remitting multiple sclerosis" Congress of the Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2002)
"Gadolinium-enhancement and brain atrophy in multiple sclerosis" 12th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2002)
"Risk factors in Multiple Sclerosis" 12th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2002)
"MRI in MS: Use of new neuroimaging techniques in diagnosis, prognosis and in evaluation of the disease-modifying treatments efficacy" ; ; Farmades Meeting (2002)
"New Diagnostic Criteria for Multiple Sclerosis" 3rd Croatian Congress of Neurology, (2001)
"Sexual dysfunction in Multiple Sclerosis; An MRI, neurophysiological and urodynamic study" 32nd Congress of the Italian Neurological Society; Congress of The Italian Neurological Society; Multiple Sclerosis (2001)
"Standardized incidence and prevalence rates in epidemiological studies on MS" 32nd Congress of the Italian Neurological Society; Italian Neurological Society; Multiple Sclerosis (2001)
"A longitudinal study of the quality of life and its relationship with cerebral volume changes in chronic, progressive multiple sclerosis patients on therapy with interferon beta-1b" Investigator Meeting; Multiple Sclerosis Investigator Meeting; Multiple Sclerosis (2001)
"Long-term effects of intravenous methylprednisolone on brain atrophy in relapsing-remitting multiple sclerosis" 27th World Congress of Neurology; World Congress of Neurology; Multiple Sclerosis (2001)
"Managing the Adverse Effects in Multiple Sclerosis patients during Interferon beta-1b therapy" ; ; Farmades Meeting (2001)
"Migraine and tension-type headache in Croatia; a population-based survey of precipitating factors" 15th Congress of the National Society of Italy per lo Studio delle Cefalee; Congresso Nazionale Societa Italiana per lo Studio delle Cefalee; Neurology (2001)
"Quality of Life in Multiple Sclerosis Patients During Interferon beta-1b therapy" Farmades Meeting (2001)
"The use of standardized incidence and prevalence rates in epidemiological studies of Multiple Sclerosis is advisable." 11th meeting of the European Neurological Society; European Neurological Society; Multiple Sclerosis (2001)
"A longitudinal study of brain atrophy and cognitive disturbances in early phase of relapsing-remitting multiple sclerosis." Autumnal meeting of Neurological Society of Triveneto; Neurological Society of Triveneto; Multiple Sclerosis (2000)
"A longitudinal study of brain atrophy and cognitive disturbances in early phase of relapsing-remitting multiple sclerosis" International Symposium on Multiple Sclerosis, (2000)
"Brain and spinal cord atrophy in multiple sclerosis: the new measures in clinical trials" Annual scientific meeting of Slovenian neurologists (2000)
"The use of NMR in diagnosing MS" European Medical Studentâ€™s Association (EMSA), 4th Croatian International Scientific Symposium, (2000)
"Olfactory dysfunction and extent of white matter abnormalities in Multiple Sclerosis; A clinical and MRI study." European Congress of Radiology; European Neurological Society; Multiple Sclerosis (2000)
"Value of different magnetic resonance imaging techniques in predicting the patterns of cognitive impairment in early phase of relapsing-remitting multiple sclerosis." European Congress of Radiology; European Congress of Radiology; Multiple Sclerosis (2000)
"Cerebral atrophy in multiple sclerosis: a new neuroradiological endpoint" Conference on MRI techniques in Multiple Sclerosis (1999)
"Incidence and prevalence of Myasthenia Gravis in the County of the Coast and Gorski Kotar, Croatia, 1976 through 1996" Annual scientific conference of the University of Rijeka, Croatia (1998)
"Assessing inflammation and neurodegeneration with MRI measures: Lessons from Multiple Sclerosis (JMC)"
"Can Imaging Techniques Measure Remyelination & Neuroprotection in MS ? (CME; GR)"
"Can we measure neuroprotection & remyelination with imaging techniques in multiple sclerosis (CME; GR)"
"Cerebral microbleeds in multiple sclerosis. A case-control Study" 6th International Society for Neurovascular Disease (ISNVD) Scientific Meeting; International Society for Neurovascular Disease
"MR non-conventional techniques and clinical correlates in MS (CME, GR)"

See all (223 more)

Service Activities:

; Treasurer - International Society for Neurovascular Diseases (2021–2024)
Zivadinov R, Zamboni P, Ge Y, Wang M. Covid-19 and neurovascular complications. 1st International Society for Neurovascular Disease webinar meeting. June 24, 2020.; Chairman (2020)
; Congressionally Directed Medical Research Development Programs (CDMRP) – Multiple Sclerosis Research (Chair of the Scientific Panel Committee) (2020–present)
Vice President of Research NSF Major Research Instrumentation Program 2020 Panel Committee Member; Panel Committee Member (2019–present)
Task Force on Safeguarding University and Faculty Assets and Interests Member; Task Force Member (2019–present)
Zivadinov R, Veroux PF, Pratesi C, De Bonis P. Headache and the Cerebral venous system. 9th Annual Meeting of the International Society for Neurovascular Disease, Ferrara, Italy, May 30, 2019:S5, p19.; Chairman (2019)
National Institute of Allergy and Autoimmune Disorders Congressionally Directed Medical Research Development Programs (CDMRP) – Neurological Research (Chair of the Scientific Panel Committee) (2018–present)
Ad Hoc Committee on Promotions to Academic (Tenurial) Ranks Member; Committee Member (2017–2020)
Mat Daemen, Zivadinov R. Imaging and mechanisms of neurodegeneration. 7th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, May 4-6, 2017.; Chairman (2017)
NIH Clinical Translational Science Institute Steering Committee Member; Committee Member (2017–present)
Directorship, Center for Biomedical Imaging, Clinical Translational Science Institute; Director (2017–present)
Zivadinov R, Mat Daemen. Heart & Brain Axis in Neurodegeneration. 6th Annual Meeting of International Society for Neurovascular Disease. New York City, NY, April 29-30, 2016.; Chairman (2016)
; Swiss MS Research Foundation (2016–present)
Zivadinov R, Alexander S. Endothelial function, lymphatic system and new drug development. 5th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, March 27-28, 2015.; Chairman (2015)
; Congressionally Directed Medical Research Programs (CDMRP) – Multiple Sclerosis Research (Scientific Reviewer) Belgium MS Research Foundation (2015–present)
Zivadinov R. A multi-modality diagnostic approach for extracranial venous disease. 4th Annual ISNVD Scientific Meeting, San Francisco, CA, February 8, 2014.; Chairman (2014)
; Congressionally Directed Medical Research Programs (CDMRP) – Multiple Sclerosis Research (Scientific Reviewer) (2014–present)
Neuroscience PhD Program: Graduate faculty member; Graduate faculty member (2014–present)
Zivadinov R, Minagar A. S29: Neurologic Manifestations of Systemic Diseases. 65th American Academy of Neurology Annual Meeting, San Diego, CA, March 20, 2013.; Chairman (2013)
MRI Directorship, Center for Biomedical Imaging, Clinical Translational Science Institute; MRI Director (2013–2017)
; Scientific member for neuroscience affairs in the Croatian Government (2013–2014)
; Executive Director - International Society for Neurovascular Diseases (2013)
; Dutch MS Research Foundation Physicians' Services Incorporated Foundation New Zealand MS Society The Research Foundation Flanders (2013–present)
Neuroscience PhD Program: Faculty member; Faculty member (2013–present)
; Leadership Committee Member (2013–present)
Senate Committee on Social Affairs, Science and Technology: Public hearing on chronic cerebrospinal venous insufficiency (CCSVI). Invited testimony on CCSVI by Dr. Robert Zivadinov, Ottawa, Canada, Nov 1, 2012.; Committee Member (2012)
Zivadinov R, Minagar A. S08: Neurologic Manifestations of Systemic Diseases. 64th American Academy of Neurology Annual Meeting, New Orleans, LA, April 24, 2012.; Chairman (2012)
; Medical Research Council Sheffield Hospital Charitable Fund (2012–present)
Zivadinov R, Luque F. S09: Neurologic Manifestations of Systemic Diseases. 63rd American Academy of Neurology Annual Meeting, Honolulu, HI, April 12, 2011.; Chairman (2011–present)
; President - International Society for Neurovascular Diseases (2011)
; Swiss National Science Foundation Netherlands Organization for Scientific Research (2011–present)
Zivadinov R, Rauchway AC. S47: Neurologic Manifestations: Clinical Neurophysiology and Epidemiology. 62nd American Academy of Neurology Annual Meeting, Toronto, CA, April 15, 2010; Chairman (2010–present)
; Canadian Institute Health Research Austrian Science Fund Saskatchewan Health Research Foundation (2010–present)
BMC Neurol - Section Editor for demyelinating diseases; Editorial Director (2010–present)
; Executive Committee Member - International Society for Neurovascular Diseases (2010–present)
President Elect - International Society for Neurovascular Diseases; President (2010–present)
Medical Research Council Grant Reviews; Reviewer (2010–present)
Austrian Science Foundation Grant Reviews; Reviewer (2010–present)
Sicotte N, Zivadinov R. Neuroimaging of MS: State of the art and future directions: What can properties of brain water (MTR, Myelin and DTI) tell? American Society of Neuroradiology: The Neuroradiology Education and Research Foundation, Washington DC, DC, Nov 7-8, 2009; Chairman (2009)
Schwendimann RN, Zivadinov R, Rauchway AC. S30: Neurologic Manifestations of Systemic Disease - Epidemiology. 61st Annual Meeting of American Academy of Neurology, Seattle, WA; Chairman (2009–present)
CTRC Imaging Committee; Committee Member (2009–present)
CTRC Translational Technologies and Resources Committee; Committee Member (2009–present)
Search Committee for Center for Brain and Behavior Informatics; Committee Member (2009–present)
; CTRC Microstructural Animal MRI Committee (2009–present)
Neuroradiology; Genome Medicine; International Journal of MS Care; Journal of Cerebral Blood Flow; Magnetic Resonance in Medicine; Reviewer (2009–present)
Jog for the Jake Committee, Jacobs Neurological Institute, Department of Neurology, University of Buffalo, 2008-2011.; Committee Member (2008–2011)
Acta Neurologica Scandinavica; Human Brain Mapping; Journal of Neuroimflammation; Image and Vision Computing; CNS Spectrum Journal Reviews; Reviewer (2008–present)
Fondazione Italiana Sclerosi Multipla Grant Reviews; Reviewer (2008–present)
Sheffield Hospitals Charitable Trust Grant Reviews; Reviewer (2008–present)
Comi G, Zivadinov R. Is MRI a reliable tool for prediction of disability progression in patients with early relapsing-remitting multiple sclerosis? European Charcot Foundation Symposium, 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Prague, (Check Republic); Chairman (2007–present)
Milonas I, Zivadinov R. Multiple Sclerosis 2. 17th meeting of European Neurological Society, Rhodos, Greece; Chairman (2007–present)
Human Brain Mapping Abstract Reviews; Reviewer (2007–present)
International Society for Magnetic Resonance Imaging Abstract Reviews; Reviewer (2007–present)
Multiple Sclerosis Scientific Research Foundation Grant Reviews; Reviewer (2007–present)
Expert Opinion in Neurology; Journal of Neuroinflammation; Future Medicine Journal Reviews; Reviewer (2007–present)
American Academy of Neurology Abstracts Review; Reviewer (2007–present)
Wellcome Trust Grant Reviews; Reviewer (2007–present)
New England Journal of Medicine; Journal of Pharmacy and Pharmacology; Journal of Interferon & Cytokine Research; BMC Neurology Journal Reviews; Reviewer (2007–present)
Multiple Sclerosis Journal Reviews; Reviewer (2006–present)
National Multiple Sclerosis Society Grant Reviews; Reviewer (2006–present)
Resident Advisory Committee; Committee Member (2005–present)
American Journal of Neuroradiology; Saudi Medical Journal, Medical Science Monitor; European Journal of Neurology; Neurology India Journal Reviews; Reviewer (2005–present)
Faculty Council; Councilor (2004–present)
Director of Resident Research Training SUNY at Buffalo, School of Medicine and Biomedical Sciences Department of Neurology/JNI; Director (2004–present)
Radiology; Journal of Neurological Sciences; Journal of Psychosomatic Research; Neuroimage; Brain; Archives of Neurology Journal Reviews; Reviewer (2004–present)
NeuroRX; Lancet Neurology; Annals of Neurology; Neurology; Journal of Neurology, Neurosurgery, Psychiatry Journal Reviews; Reviewer (2003–present)
Journal of Neuroimaging; Journal of American Medical Association; Drugs Journal Reviews; Reviewer (2001–present)
Veins and Lymphatics - Editorial board member
Word Journal of Surgical Procedures - Editorial board member
; BioMed Res Int - Editorial board member
; BMC Med - Editorial board member
Zivadinov R, Yiu Bai. Extracranial venous disease. 8th Annual Meeting of International Society for Neurovascular Disease. Naples, Italy, May 31-June 2, 2018.; Chairman
Zivadinov R, Reid D, Petrov I, Salvi F. Indication for CCSVI treatment. 9th Annual Meeting of the International Society for Neurovascular Disease, Ferrara, Italy, May 30, 2019:S4, p18.; Chairman
Zivadinov R. COVID-19: aerosol transmission, pathogenesis and vaccines: Pathogenesis and vaccines of COVID-19. 5th International Society for Neurovascular Disease webinar meeting. March 4, 2021.; Chairman
; Clinical CNS Drugs - Editorial board member
Jog for Jake Committee Jacobs Neurological Institute; Committee Member
; Conference Papers in Neuroscience - Editorial board member
; Journal of Alzheimer's Disease - Associate Editor
; Neurovascular Imaging - Editorial board member
; Quantitative Imaging in Medicine and Surgery- Editorial board member
; Translational Neuroscience - Editorial board member

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

scroll-out

Contact Information

Buffalo Neuroimaging Analysis Center
D-2 Buffalo General Hospital
100 High St
Buffalo, New York 14203
Phone: (716) 859-7040
Fax: (716) 859-7066
rz4@buffalo.edu

View map

View faculty website

Robert Zivadinov MD, PhD

Robert Zivadinov
MD, PhD

Specialty/Research Focus

Professional Summary:

Education and Training:

Employment:

Awards and Honors:

Research Expertise:

Research Centers:

Grants and Sponsored Research:

Patents:

Journal Articles:

Abstracts:

Professional Memberships:

Presentations:

Service Activities:

School News:

In the Media:

Clinical Specialties:

Clinical Offices:

Insurance Accepted:

Contact Information

PhD Program in Biomedical Sciences

Connect With Us

Jacobs School of Medicine and Biomedical Sciences

About The School

Education and Training

Centers and Affiliations

Find People

Resources by Audience

Alumni and Friends

Research Facilities and Services

Get Involved

Learning Resources

Support Services

Site Tools